{
    "0": {
        "output": "To determine the trial-level eligibility for the patient described in the note, we must compare the patient's characteristics and situation with the inclusion and exclusion criteria of the clinical trial.\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions noted on CXR\n- No prior chemotherapy, candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Women of any age with clinical stage II breast cancer\n- Primary tumor \u2264 5 cm in size with axillary lymph nodes which are clinically [N0 or N1] [T1N1, T2N0, T2N1]\n- No definitive local therapy or prior chemotherapy\n- Histologic confirmation of invasive carcinoma\n- Geographically accessible for follow-up\n- Mentally competent to understand and give informed consent\n- ER status can be positive, negative, or unknown\n- Patients with prior cancers may be eligible if no evidence of recurrence for \u2265 10 years\n\nClinical Trial Exclusion Criteria:\n- Advanced local disease or distant metastases (stage III or IV)\n- Previous therapy to the breast other than excisional biopsy\n- Pregnancy\n- Unwillingness to use birth control during chemotherapy\n- Chronic disease that may affect the risk for surgery or chemotherapy\n\nBased on the patient note, the patient has stage II breast cancer with axillary lymph node involvement, and no previous chemotherapy, which aligns with the inclusion criteria. However, the patient has metastatic lesions as noted on CXR, which suggests advanced disease beyond stage II.\n\nThis falls under the exclusion criteria, which states that patients with advanced local disease or distant metastases (stage III or IV) are not eligible to participate.\n\nTherefore, the patient would be excluded from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, let's compare the patient note with the inclusion criteria of the trial:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes, axillary sampling\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female with histologically confirmed nonlobular invasive breast cancer (ductal, papillary, medullary, colloid (mucinous), or tubular)\n- Stage I/II (T1-2 N0-1 M0) tumor no greater than 3 cm\n- Prior tylectomy and axillary lymph node dissection required\n- No more than 3 positive axillary lymph nodes and no extracapsular extension\n- At least 6 lymph nodes sampled OR Negative sentinel node\n- Surgical clips in place delineating margins of tylectomy cavity\n- Negative, or close but negative, inked histologic margins of tylectomy or re-excision specimen\n- No extensive intraductal carcinoma by the Harvard definition\n- No proven multicentric carcinoma\n- No skin or chest wall invasion, matted or fixed axillary adenopathy, metastatic internal mammary or supraclavicular nodes, or Paget's disease of the nipple\n- No previously treated contralateral breast carcinoma or synchronous bilateral breast carcinoma\n- No prior chemotherapy for breast cancer\n- No prior radiotherapy for breast cancer\n- Planned chemotherapy may begin at least 2 weeks after removal of brachytherapy catheters\n\nAssessment:\n- The patient has ductal breast cancer, which is one of the eligible histologies.\n- The patient has a tumor no greater than 3 cm.\n- The patient has 5 positive lymph nodes, which exceeds the trial's maximum of 3 positive nodes.\n- The patient has metastatic lesions present on CXR, indicating metastasis (M1), which exceeds the Stage I/II (T1-2 N0-1 M0) requirement.\n- The patient is a candidate for tumor resection, which aligns with the requirement for prior tylectomy and axillary lymph node dissection.\n\nBased on the above comparison, the patient does not meet the trial's inclusion criteria due to having more than 3 positive lymph nodes and the presence of metastatic lesions. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial titled \"S9630, Medroxyprogesterone in Treating Women With Breast Cancer.\"\n\nPatient's characteristics and condition:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma (HER2-positive and ER/PR negative)\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions visible on chest x-ray (CXR)\n- Candidate for tumor resection followed by chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically proven diagnosis of one of the following:\n  - Primary invasive adenocarcinoma of the unilateral or bilateral breast\n  - Stage I, IIA, or IIB (T1-3, N0-1, M0)\n- No recurrent invasive breast cancer\n- No sarcoma, lymphoma, or specific types of cancer of the breast not mentioned in the patient's note\n- Currently free of breast cancer (no evidence of disease)\n- No evidence of distant disease on chest x-ray or chest CT scan\n- Prior definitive local treatment of primary lesion and axillary node or sentinel node biopsy\n- Postmenopausal status as defined in the criteria\n- Candidate for adjuvant tamoxifen therapy\n\nBased on the information provided:\n- The patient has histologically confirmed invasive ductal breast carcinoma and is postmenopausal, which aligns with the trial's requirements.\n- However, the patient is not currently free of breast cancer as she has metastatic lesions visible on CXR.\n- The patient is a candidate for tumor resection, which suggests she has not yet had definitive local treatment of the primary lesion.\n\nThe patient does not meet key inclusion criteria:\n- No evidence of distant disease on chest x-ray or chest CT scan.\n- Prior definitive local treatment of the primary lesion.\n\nDue to the presence of metastatic lesions and the lack of prior definitive local treatment, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "3": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Combination Chemotherapy in Treating Women With Breast Cancer\":\n\nPatient Characteristics:\n- Age: 45 years old (meets age criterion)\n- Sex: Female (trial is for women, meets sex criterion)\n- Menopausal status: Postmenopausal (not specified as a factor in the trial)\n- Disease: Cytologically confirmed breast cancer (meets disease characteristic)\n- Tumor size: 3 cm invasive ductal carcinoma (meets tumor size criterion)\n- Lymph nodes: 5 positive lymph nodes (trial specifies 1 to 3 positive lymph nodes)\n\nAdditional Considerations:\n- Metastatic lesions noted in CXR (the trial excludes metastatic breast cancer)\n- Hormone receptor status: HER2-positive and ER/PR negative (not specified as a factor in the trial)\n- No information on hematopoietic, hepatic, renal, or cardiovascular status is given, but these are part of the inclusion criteria to ensure adequate organ function.\n- No prior chemotherapy for the malignancy (meets prior/concurrent therapy criterion)\n- No information on prior radiotherapy specific to the malignancy in question.\n- The patient is a candidate for tumor resection and agrees to do so (meets surgical requirements if done within 84 days before beginning treatment on protocol).\n\nBased on the provided information, the patient meets some of the inclusion criteria (age, sex, disease confirmation, undergoing surgery), but the trial specifically excludes patients with locally advanced or inflammatory or metastatic breast cancer, which this patient has (metastatic lesions noted in CXR). Additionally, the patient has more positive lymph nodes (5) than the trial's specified range (1 to 3).\n\nTherefore, the patient is not eligible for the trial due to the exclusion criteria regarding metastatic cancer and the number of positive lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "4": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical trial's inclusion criteria:\n- Histologically or cytologically proven stage I or IIA invasive breast cancer\n- Tumor size T0, T1, or T2 (no greater than 3 cm)\n- N0 (no lymph node involvement)\n- Noninflammatory\n- Nonmetastatic\n- Eligible for breast-conserving surgery\n- Hormone receptor status: Positive or negative\n- No allergies to radiopharmaceuticals or blue dye\n- No prior breast surgical biopsy or axillary surgery\n- No prior neoadjuvant therapy (biological, chemotherapy, endocrine, or radiotherapy)\n\nComparing the patient's characteristics to the inclusion criteria:\n\n- The patient does have histologically confirmed invasive breast cancer, matching the trial criteria.\n- The tumor size is within the specified limit (3 cm), which is T2 and meets the trial criteria.\n- The patient has positive lymph nodes (N1), which is not compatible with the trial's requirement of N0.\n- The patient has metastatic lesions, which means she does not meet the nonmetastatic requirement of the trial.\n- The patient is postmenopausal, which is allowed in the trial as it accepts both pre- and postmenopausal women.\n\nBased on the above comparison, the patient does not meet the inclusion criteria due to the presence of positive lymph nodes and metastatic disease. The trial specifies N0 (no lymph node involvement) and nonmetastatic patients, which excludes this patient from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "5": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria Assessment:\n1. Disease Characteristics:\n   - Resectable invasive adenocarcinoma of the breast: The patient has invasive ductal breast carcinoma, which is a type of adenocarcinoma. It is not explicitly stated whether it is resectable, but the patient is a candidate for tumor resection, which implies that it is likely resectable.\n   - Clinically negative lymph nodes: The patient has 5 positive lymph nodes, which disqualify her based on this criterion.\n   - No positive ipsilateral axillary lymph nodes: The patient has positive lymph nodes, which disqualify her.\n   - No prior removal of ipsilateral axillary lymph nodes: There is no information provided that suggests prior removal.\n   - No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy: There is no information about this in the patient's note.\n   - No ulceration, erythema, infiltration of the skin or underlying chest wall, peau d'orange, or skin edema: There is no information about this in the patient's note.\n   - No bilateral malignancy or mass in the opposite breast that is suspicious for malignancy, unless proven nonmalignant by biopsy: There is no information suggesting a contralateral breast issue.\n   - No diffuse tumors or multiple malignant tumors in different quadrants of the breast: There is no information provided regarding this.\n   - No other prior breast malignancy except lobular carcinoma in situ: It is not mentioned if the patient has had any other prior breast malignancy.\n   - No prior or concurrent breast implants: There is no mention of breast implants.\n\n2. Patient Characteristics:\n   - Age: 18 years and older: The patient is 45 years old.\n   - Sex: Female: The patient is a postmenopausal woman.\n   - Life expectancy: At least 10 years (excluding diagnosis of cancer): There is no information provided regarding life expectancy, but nothing suggests it is less than 10 years.\n   - No hepatic systemic disease: There is no information about hepatic disease.\n   - No renal systemic disease: There is no information about renal disease.\n   - No cardiovascular systemic disease: There is no information about cardiovascular disease.\n   - No prior malignancy within the past 5 years except for certain exceptions: There is no information about previous malignancies.\n   - No concurrent psychiatric or addictive disorder: There is no information about psychiatric or addictive disorders.\n\n3. Prior Concurrent Therapy:\n   - No prior immunotherapy, chemotherapy, hormonal therapy, or radiotherapy for this cancer: The patient is not reported to have undergone any of these treatments.\n   - No prior breast reduction surgery: There is no information about previous breast reduction surgery.\n   - Prior excisional biopsy or lumpectomy allowed: The patient has had a core biopsy, which is not explicitly excluded.\n\nThe patient does not meet the inclusion criteria due to having positive lymph nodes, which is specifically mentioned as an exclusion under the disease characteristics.\n\nTherefore, the patient would be excluded from the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "6": {
        "output": "Based on the provided clinical trial inclusion criteria and the patient note, let's compare the relevant points:\n\nInclusion Criteria Check:\n\n1. **Histologically confirmed resectable adenocarcinoma of the breast**: The patient has cytologically confirmed breast cancer, which is an invasive ductal carcinoma. This meets the criterion for breast adenocarcinoma.\n\n2. **Postmenopausal**: The patient is described as postmenopausal which fits the inclusion criterion.\n\n3. **No distant metastases**: The patient has metastatic lesions as per the chest x-ray (CXR), indicating distant metastases. This does not meet the criterion that specifies no distant metastases.\n\n4. **Hormone receptor status**: The patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria specify that the tumor must have at least 10% hormone receptor-positive cells, which would include estrogen receptor (ER) and/or progesterone receptor (PR) positivity. The patient's tumor does not meet this criterion as it is ER/PR negative.\n\n5. **Agreement to tumor resection prior to chemotherapy**: The patient agrees to have tumor resection before chemotherapy, which aligns with the requirement for patients to have had surgery (total mastectomy, lumpectomy, or quadrantectomy).\n\nBased on the criteria mentioned above, the patient does not meet the hormone receptor status and has distant metastases, which excludes her from participating in this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "7": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient note to the inclusion criteria provided by the trial. Let's go through the main points:\n\nInclusion criteria for the trial:\n\n1. HER2 overexpressing (3+) metastatic breast cancer by immunohistochemistry, or amplified by FISH.\n2. No prior chemotherapy for breast cancer metastases.\n3. No bilateral disease.\n4. Bidimensionally measurable disease with at least one target lesion greater than 1 cm2.\n5. No significant lymphedema in the arm ipsilateral to the mastectomy site, unless the patient has an indwelling catheter for the purpose of chemotherapy infusion.\n6. No CNS metastases.\n7. Female patients aged 18 and over.\n8. Karnofsky performance status 70-100%.\n9. Adequate hematopoietic function (specific blood count levels).\n10. Adequate hepatic function (specific enzyme levels).\n11. Adequate renal function (creatinine no greater than 1.5 times ULN).\n12. No clinically significant cardiovascular disease.\n13. Left ventricular ejection fraction at least 50%.\n14. No severe hypersensitivity to products containing Cremophor EL.\n15. Not pregnant or nursing, and using effective contraception if fertile.\n\nPatient note:\n\n1. 45-year-old postmenopausal woman with cytologically confirmed breast cancer (meets gender and age criteria).\n2. HER2-positive and ER/PR negative tumor in the left upper outer quadrant (meets HER2 overexpression criteria).\n3. Axillary sampling revealed 5 positive lymph nodes (not specified as exclusion criteria).\n4. Tumor is 3 cm invasive ductal breast carcinoma, suggesting measurable disease (meets measurable disease criteria).\n5. CXR showed metastatic lesions (indicates metastatic breast cancer, but CNS involvement is not mentioned).\n6. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy (no prior chemotherapy for metastases is mentioned, which meets criteria).\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria for the clinical trial. The patient has HER2-positive metastatic breast cancer, which is required by the trial, and there is no mention of any prior chemotherapy for metastases, bilateral disease, CNS metastases, or significant lymphedema that would exclude the patient. Additionally, there is no indication of any other serious medical conditions, which is also in line with the patient characteristics required by the trial.\n\nHowever, there are some criteria for which we do not have enough information, such as the Karnofsky performance status, hematopoietic, hepatic, renal function, cardiovascular health, and left ventricular ejection fraction. We also do not have information regarding any prior treatments such as chemotherapy in an adjuvant setting, which could potentially exclude the patient if the specific conditions are not met.\n\nGiven the available information, the patient appears to be potentially eligible, but there is insufficient information to definitively determine eligibility without further details on the patient's medical history and current health status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "8": {
        "output": "To determine the trial-level eligibility of the patient, we need to compare the patient's information with the inclusion criteria of the clinical trial. Let's assess the patient's eligibility based on the provided inclusion criteria:\n\n1. **Age**: The patient is 45 years old, which meets the age requirement of being \u2265 18 years.\n2. **Diagnosis**: The patient has cytologically confirmed breast cancer, which meets the requirement of having operable, histologically confirmed adenocarcinoma of the female breast.\n3. **Tumor Characteristics**: The patient has a HER2-positive and ER/PR-negative invasive ductal carcinoma with 5 positive lymph nodes, which meets the criteria for node-positive disease with HER-2 positive status.\n4. **Surgical candidacy**: The patient is a candidate for tumor resection, which aligns with the requirement that all tumor should be removed via surgery.\n5. **Treatment History**: The patient note does not mention prior chemotherapy, hormonal therapy, or radiation therapy, which is consistent with the trial\u2019s requirements that certain treatments must not have been received before registration.\n6. **Other Health Conditions**: The patient note does not list any other health conditions that would exclude her from the trial based on the provided criteria.\n7. **Willingness**: The patient agrees to tumor resection, which indicates a willingness to undergo necessary treatments and potentially meet the requirement for informed consent.\n\nGiven the information in the patient note, the patient seems to meet all the mentioned inclusion criteria for the clinical trial. However, it is important to note that there are certain criteria for which we do not have information, such as laboratory values (ANC, PLT, bilirubin, AST, LVEF), willingness to discontinue sex hormonal therapy, and non-breast malignancies. The patient's eligibility would also be contingent on the results of these criteria.\n\nSince we do not have information about these factors, we cannot definitively determine the patient's eligibility. Therefore, based on the information provided and the fact that we lack some details necessary for a complete assessment, the trial-level eligibility would be:\n\n`Trial-level eligibility: 1) Not relevant.`",
        "label": 2
    },
    "9": {
        "output": "Let's evaluate the patient's eligibility based on the inclusion criteria provided for the clinical trial.\n\n**Patient Information:**\n- Age: 45 years old\n- Sex: Female\n- Menopausal status: Postmenopausal\n- Breast cancer: Cytologically confirmed\n- Tumor characteristics: 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative\n- Lymph nodes: 5 positive axillary lymph nodes\n- Metastasis: Presence of metastatic lesions (CXR)\n- Treatment plan: Candidate for tumor resection prior to chemotherapy\n\n**Clinical Trial Inclusion Criteria:**\n- Stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV primary carcinoma of the breast\n- No excisional biopsy\n- Tumor size 2 nodes 1 (T2N1) or tumor size 3 nodes 0 (T3N0)\n- Any T with N2 (including axillary lymph nodes matted to one another) or N3\n- Any T4, including inflammatory breast cancer\n- Adjuvant patients with at least 4 positive lymph nodes and HER-2 overexpressing tumor\n- Supraclavicular or infraclavicular positive lymph nodes without distant metastases\n- Distant metastases with measurable disease in breast or lymph nodes\n- Synchronous bilateral primary breast cancer if the more serious cancer meets entry criteria\n- Measurable or evaluable disease\n- Female\n- Not pregnant or nursing\n- Negative pregnancy test\n- Fertile patients must use effective contraception\n- Hematopoietic and organ function criteria specified\n\n**Clinical Trial Exclusion Criteria:**\n- Prior malignancies except in specific cases\n\nThe patient has a confirmed diagnosis of breast cancer with positive lymph nodes and metastatic lesions, indicating advanced disease. The tumor is HER2-positive, which corresponds with the HER-2 overexpressing tumor criterion. The patient's cancer stage is not explicitly mentioned, but the presence of positive lymph nodes and distant metastases suggests that she could fall into the stage IIIB, IIIC, or IV categories, which are included in the trial. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which aligns with the trial's treatment approach.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial: she has breast cancer with axillary lymph node involvement, HER2-positive tumor, and distant metastases, which are all characteristics specified in the inclusion criteria.\n\nTherefore, the patient is likely to be eligible for the trial unless there are other unstated exclusion criteria that she meets or if her tumor size and stage do not exactly match those specified.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "10": {
        "output": "To determine the patient's trial-level eligibility, we need to compare the patient's information to the inclusion and exclusion criteria of the clinical trial \"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study.\"\n\nPatient's characteristics:\n- Age: 45 years old\n- Postmenopausal (implied by the term \"postmenopausal woman\")\n- Cytologically confirmed breast cancer\n- Known tumor characteristics (HER2-positive, ER/PR negative)\n- Axillary sampling showed 5 positive lymph nodes\n- Metastatic lesions present\n- Candidate for tumor resection\n- No mention of BRCA mutation or relationship to BRCA mutation carriers\n- No information about menstrual history or FSH level\n- No information on ECOG performance status\n- Willingness to undergo tumor resection implies ability to provide informed consent\n\nInclusion criteria for the Menstrual Cycle Study:\n- Must be at least 25 years old and less than 46 years old\n- Must be premenopausal with regular menstrual cycling\n- Must have a known BRCA mutation or be a relative of someone with a BRCA-associated cancer\n- Willing to use non-hormonal contraception\n- ECOG performance status of 0-1\n- Able to provide informed consent\n\nExclusion criteria for the Menstrual Cycle Study:\n- Menstrual cycle irregularities\n- Use of certain hormonal medications\n- Pregnancy or lactation within 12 months\n- History of certain medical conditions (e.g., invasive cancer, abnormal CA-125)\n- Over a certain weight limit\n- Allergies to specific substances\n\nBased on the provided information, the patient does not meet the inclusion criteria for the Menstrual Cycle Study as she is postmenopausal, which is directly in conflict with the requirement for participants to be premenopausal with regular menstrual cycling. Additionally, there is no information suggesting that the patient is a known BRCA mutation carrier or a relative of a BRCA mutation carrier, which is another key inclusion criterion. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "11": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman (meets age and sex criteria)\n- Breast cancer confirmed by core biopsy (meets criteria for confirmed invasive breast cancer)\n- HER2-positive and ER/PR negative (hormone receptor status not specified in the trial's criteria)\n- Has metastatic lesions (does not meet criteria as metastatic disease is excluded)\n- Candidate for tumor resection (implies the patient is fit for surgery, potentially meeting the fitness criteria)\n\nTrial Inclusion Criteria:\n- Histologically confirmed operable invasive breast cancer (met by patient)\n- T0-2, N0 (patient has positive lymph nodes, thus exceeding the N0 criteria)\n- Only 1 tumor in 1 breast (met by patient)\n- Tumor between 5 and 50 mm in largest diameter, within 1 quadrant (met by patient)\n- No metastatic disease (patient does not meet this criterion)\n- Clinically negative axillary lymph nodes (patient has 5 positive lymph nodes, thus not meeting this criterion)\n- Fit to undergo sentinel node biopsy, axillary clearance, breast surgery, and/or axillary radiotherapy (presumably met by patient)\n- No psychological, familial, sociological, or geographical condition that would preclude study compliance (there is no information to suggest non-compliance)\n- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix (met by patient)\n- Not pregnant (met by patient)\n\nThe patient does not meet the criteria for T0-2, N0 due to having positive lymph nodes and has disqualifying metastatic disease. Therefore, the patient would be excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "12": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions observed on CXR\n- Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically or cytologically confirmed metastatic breast cancer with HER2 overexpression (\u2713 the patient's tumor is HER2-positive)\n- Radiographically or physically measurable disease that can be biopsied safely under local anesthesia (\u2713 the patient has a 3 cm tumor and metastatic lesions)\n- Age 18 and over (\u2713 the patient is 45 years old)\n- Male or female (\u2713 the patient is female)\n- ECOG performance status 0-2 (not specified in the patient note, so we cannot confirm)\n- Neutrophil count at least 1,000/mm^3 (not specified in the patient note)\n- Platelet count at least 75,000/mm^3 (not specified in the patient note)\n- Bilirubin no greater than 3 times ULN (not specified in the patient note)\n- AST and ALT no greater than 5 times ULN (not specified in the patient note)\n- Not pregnant or nursing (\u2713 the patient is not sexually active and has no children)\n- Negative pregnancy test (not specified, but the patient is postmenopausal and not sexually active, so pregnancy is unlikely)\n- Fertile patients must use effective contraception (not applicable, the patient is postmenopausal)\n- No prior trastuzumab (not specified in the patient note, so we cannot confirm)\n- At least 2 weeks since prior hormonal therapy (not specified, but the patient is postmenopausal and no hormonal therapy is mentioned)\n- No concurrent hormone receptor therapy (e.g., tamoxifen or armidex) (not specified, but no current therapy is mentioned)\n- Localized palliative external beam radiotherapy allowed (not relevant to the patient's current treatments)\n\nBased on the information provided, the patient meets several of the specified inclusion criteria for the clinical trial. However, crucial information regarding performance status, blood counts (neutrophil and platelet), liver function (bilirubin, AST, ALT), and prior trastuzumab use is not provided in the patient note. Without this information, we cannot definitively determine the patient's eligibility. Therefore, the patient's eligibility is assessed as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "13": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\n**Patient Note Analysis:**\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- Tumor characteristics: invasive ductal breast carcinoma, HER2-positive, ER/PR-negative.\n- The patient has metastatic lesions (indicating metastatic breast cancer).\n- The patient is using multivitamins and iron supplements.\n- The patient does not smoke or consume alcohol.\n- The patient is not sexually active and has no children.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\n**Clinical Trial Inclusion Criteria:**\n- Postmenopausal women.\n- Metastatic breast cancer suitable for endocrine therapy.\n- Positive hormone receptor status.\n- Human epidermal growth factor receptor 2 (HER2) overexpression.\n\n**Eligibility Assessment:**\n- The patient is a postmenopausal woman (meets criteria).\n- The patient has metastatic breast cancer (meets criteria).\n- The patient has a HER2 overexpressing tumor (meets criteria).\n- The inclusion criteria require a positive hormone receptor status (ER+ve and/or PR+ve), and the patient's tumor is ER/PR-negative, which does not meet the hormone receptor positivity requirement of the trial.\n\nSince the patient does not meet the requirement of having a positive hormone receptor status, as her tumor is ER/PR-negative, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "14": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition against the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical trial inclusion criteria for breast cancer and high-risk patients:\n- Age \u2265 18 years and \u2264 74 years (Patient is 45, so meets this criterion)\n- Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin (Patient has invasive ductal breast carcinoma, so meets this criterion)\n- Breast cancer may be invasive or noninvasive, and in the past or the present (Patient has current invasive breast cancer, so meets this criterion)\n- The contralateral breast must be free of any suspicious areas by physical examination and mammogram (There is no information about the contralateral breast, but since there is no mention of issues, we can assume it meets this criterion unless proven otherwise)\n- WBC greater than 2,500 (Not mentioned, so we don't know)\n- Platelets greater than 50,000 (Not mentioned, so we don't know)\n\nExclusion criteria for breast cancer patients:\n- Contralateral breast prosthesis (Not mentioned, so we assume it does not apply)\n- Pregnancy (Not mentioned, but given she is not sexually active, we can assume she is not pregnant)\n- History of radiation therapy to the contralateral breast (Not mentioned, so we assume it does not apply)\n- Lactating breasts (Not mentioned, but as she is postmenopausal and not sexually active, we assume it does not apply)\n- Chemotherapy within the past 1 month (Not mentioned, so we don't know)\n- Current antiestrogen therapy (Not mentioned, so we don't know)\n- Current hormonal replacement therapy or oral contraceptives (Not mentioned, but given she is postmenopausal and not sexually active, we assume she is not on contraceptives)\n- Concurrent infection (Not mentioned, so we assume it does not apply)\n- Previous contralateral major duct excision (Not mentioned, so we assume it does not apply)\n\nBased on the available information, the patient appears to meet the inclusion criteria, as she is a postmenopausal woman within the age range with confirmed breast cancer of epithelial origin. However, we lack information on her WBC and platelet counts, chemotherapy within the past month, and if she is currently on any antiestrogen therapy. \n\nWithout complete information, we cannot definitively include or exclude the patient; thus, she falls under the \"Not relevant\" category as we lack sufficient information to qualify her for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "15": {
        "output": "To determine the trial-level eligibility for this patient, we need to match the patient's details against the inclusion criteria of the clinical trial.\n\nPatient details:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor size: 3 cm\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions noted on CXR\n- No mention of previous chemotherapy or hormonal therapy for this malignancy\n- Candidate for tumor resection before chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically confirmed invasive carcinoma of the female breast\n- 0-3 positive axillary lymph nodes\n- Patients with 1-3 positive axillary nodes are eligible if chemotherapy is deemed potentially beneficial\n- Negative tumor margins for invasive cancer and DCIS\n- No previous trastuzumab, chemotherapy or hormonal therapy for this malignancy\n- No previous anthracycline chemotherapy for any disease\n- No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer\n- No involvement of dermal lymphatics on pathology\n- Disease-free from prior malignancies for > 5 years (with specific exceptions)\n- CTC performance status 0-1\n- Not pregnant or nursing\n- No concomitant exogenous hormone therapy\n- Adequate organ function\n- No active congestive heart failure or recent myocardial infarction\n\nBased on the information provided, the patient has metastatic breast cancer, which is indicated by the presence of metastatic lesions on CXR. As the clinical trial specifically excludes patients with metastatic breast cancer, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "16": {
        "output": "",
        "label": 2
    },
    "17": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer,\" we need to compare the patient's characteristics and history with the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm, located in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Metastatic lesions present (implying Stage IV or locally advanced disease)\n- Axillary sampling revealed 5 positive lymph nodes\n- Candidate for tumor resection, chemotherapy not started yet\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed breast cancer\n- Stage IV or locally advanced disease\n- HER2/neu positive by FISH (if 2+ by IHC) or 3+ by IHC\n- Measurable or evaluable disease\n- Estrogen receptor and/or progesterone receptor positive\n- Postmenopausal woman\n- Age 18 and over\n- ECOG performance status 0-2\n- Adequate hepatic and renal function\n- Ejection fraction greater than 50%\n- No prior treatment with trastuzumab or exemestane\n\nComparison:\n- The patient's breast cancer is histologically confirmed, meeting the trial requirement.\n- The patient has HER2-positive breast cancer, which is a requirement for the trial.\n- The patient's tumor size and the presence of metastatic lesions indicate that she has either stage IV or locally advanced disease.\n- The patient is postmenopausal, as per the information provided.\n- The patient's performance status is not mentioned, but since she is a candidate for surgery, it can be inferred that she likely has an ECOG performance status of 0-2.\n- The patient has not received trastuzumab or exemestane, which aligns with the trial's criteria.\n- The patient's hormone receptor status is negative for ER/PR, which does not meet the trial's requirement of being positive for estrogen receptor and/or progesterone receptor.\n\nBased on the provided information, the patient meets several of the trial's inclusion criteria. However, she does not meet the criteria for hormone receptor status, as she is ER/PR negative while the trial requires participants to be estrogen receptor and/or progesterone receptor positive.\n\nTherefore, the patient is not eligible for the trial due to a mismatch in hormone receptor status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "18": {
        "output": "To determine the trial-level eligibility of the patient for the \"Premenopausal Endocrine Responsive Chemotherapy Trial,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nBased on the patient note:\n- Age: 45 years old\n- Sex: Female\n- Menopausal status: Postmenopausal\n- Diagnosis: Invasive ductal breast carcinoma, HER2-positive and ER/PR negative\n- Additional details: Axillary sampling revealed 5 positive lymph nodes, metastatic lesions present on CXR, candidate for tumor resection prior to chemotherapy\n\nBased on the trial inclusion criteria:\n- Disease Characteristics: Breast cancer confined to breast and axillary nodes, no distant metastatic disease, certain surgical criteria\n- Hormone receptor status: Estrogen receptor and/or progesterone receptor positive\n- Patient Characteristics: Premenopausal, premenopausal estradiol levels, no prior or concurrent invasive malignancy other than specified exceptions\n- Other: No prior neoadjuvant or adjuvant chemotherapy or endocrine therapy, among other specific criteria\n\nComparison:\n- The patient's age and sex fit the trial criteria.\n- The patient is postmenopausal, which does not fit the premenopausal requirement of the trial.\n- The patient's tumor is HER2-positive and ER/PR-negative, which does not meet the hormone receptor positive requirement of the trial.\n- The patient has distant metastatic disease, as indicated by the metastatic lesions present on CXR, which does not meet the \"no distant metastatic disease\" requirement of the trial.\n\nTherefore, the patient does not meet the key inclusion criteria of being premenopausal and having hormone receptor positive breast cancer and does not fit the requirement of no distant metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "19": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer,\" we need to compare the patient's information to the trial's inclusion criteria.\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma (HER2-positive, ER/PR-negative)\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present on CXR\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Histologically confirmed stage I-III invasive breast cancer (Patient meets this criterion)\n- Operable disease (Patient meets this criterion with planned tumor resection)\n- Stage I, II, IIIA, and IIIC (T1-3, N3a only) (Patient's disease seems to fit within these stages)\n- No T4 tumors (No T4 tumor mentioned in the patient note)\n- High-risk disease, defined by specific tumor sizes, node status, and other factors (Patient meets this criterion with a tumor \u2265 2 cm and positive lymph nodes)\n- HER2/neu-positive tumors allowed (Patient's tumor is HER2-positive)\n- Prior surgery requirements (Patient is a candidate for surgery)\n- Resection margins must be negative for invasive cancer (Patient has not yet had surgery, so this is not applicable yet)\n- Age 18 and over (Patient is 45 years old)\n- Zubrod performance status of 0-2 (Not mentioned, but nothing suggests the patient wouldn't meet this criterion)\n- Adequate hematopoietic, hepatic, renal, and cardiovascular function (No information given, but nothing suggests the patient wouldn't meet these criteria)\n- No other malignancy within the past 5 years (Patient note does not mention any other malignancy)\n- No prior cytotoxic chemotherapy for this breast cancer (Patient has not received chemotherapy yet)\n- No prior chemotherapy with an anthracycline, anthracenedione, or taxane (Patient has not received chemotherapy yet)\n- Not pregnant or nursing, and using effective contraception if fertile (Patient is postmenopausal and not sexually active)\n\nBased on the available information, the patient appears to meet all the disclosed inclusion criteria for the clinical trial. The patient note does not provide information that would lead to exclusion based on the trial criteria provided. Therefore, the patient seems eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "20": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases,\" we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nHere are the key inclusion criteria to consider:\n\n1. Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma.\n2. Largest tumor lesion \u2264 5 cm.\n3. Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions.\n4. Prior (preoperative) or planned (intraoperative) sentinel node biopsy required.\n5. At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension.\n6. No clinical evidence of distant metastases.\n7. No palpable axillary lymph node(s).\n8. No other prior or concurrent malignancy except for certain treated conditions.\n9. No prior systemic therapy for breast cancer.\n\nPatient note analysis:\n\n1. The patient has a diagnosis of breast cancer.\n2. The tumor is 3 cm, which is within the criterion of \u2264 5 cm.\n3. There is no mention of the method of localization for the tumor, but since surgery is planned, it is likely that some form of localization will be or has been used.\n4. The patient's note does not specify whether a sentinel node biopsy has been performed or planned.\n5. The patient has 5 positive lymph nodes, which indicates metastases larger than micrometastases and may have extracapsular extension.\n6. There is clinical evidence of distant metastases (CXR remarkable for metastatic lesions).\n7. Since there are 5 positive lymph nodes, it is likely that they are palpable, which is against the inclusion criteria.\n8. There is no mention of any other prior or concurrent malignancy.\n9. There is no prior systemic therapy for breast cancer mentioned.\n\nBased on the information provided, the patient does not meet the following key inclusion criteria: having only micrometastatic sentinel lymph nodes with no extracapsular extension and no clinical evidence of distant metastases. The presence of distant metastases and more than micrometastatic involvement of the lymph nodes excludes the patient from participating in the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "21": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the trial.\n\nAccording to the patient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has a confirmed diagnosis of breast cancer, specifically invasive ductal breast carcinoma, which is different from ductal carcinoma in situ (DCIS).\n- The tumor is HER2-positive and ER/PR negative, which means it does not meet the hormone receptor status required for the trial (estrogen or progesterone receptor positive with at least 5% positive cells).\n- The patient has metastatic lesions, as indicated by the CXR results.\n\nNow, let's review the inclusion criteria of the clinical trial:\n- Diagnosis of ductal carcinoma in situ within the past 6 months.\n- Locally excised with tumor-free margins at least 1 mm.\n- Hormone receptor status: Estrogen or progesterone receptor positive with equal to or greater than 5% positive cells.\n- Age between 40 to 70 years.\n- Postmenopausal status (the patient is postmenopausal).\n- No prior deep vein thrombosis, transient ischemic attack, or cerebrovascular accident.\n- No prior pulmonary embolism.\n- No unexplained postmenopausal bleeding.\n- No other cancer within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix.\n- No other concurrent medical condition that would preclude study therapy, place the patient at unusual risk, or confound study results.\n- No evidence of osteoporosis, except allowed conditions.\n- No prior or concurrent tamoxifen use lasting more than 6 months unless treatment was completed more than 5 years ago.\n- No prior or concurrent raloxifene use lasting more than 6 months unless treatment was completed more than 5 years ago.\n- No other prior or concurrent selective estrogen-receptor modulator use lasting more than 6 months unless treatment was completed more than 5 years ago.\n- No concurrent systemic estrogen-based hormone replacement therapy, including vaginal estrogen preparations.\n- No prior mastectomy.\n- No planned prophylactic mastectomy.\n- At least 3 months since prior unapproved or experimental agents.\n- No concurrent anticoagulants.\n\nBased on the patient note and the clinical trial inclusion criteria, the patient does not meet the key eligibility requirement of having a diagnosis of ductal carcinoma in situ. Instead, she has invasive ductal breast carcinoma, which is not the focus of this trial. Additionally, her tumor does not meet the hormone receptor status required for the trial (the tumor is HER2-positive and ER/PR negative, whereas the trial requires ER or PR positivity). Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "22": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed metastatic breast cancer. The core biopsy has revealed invasive ductal breast carcinoma, HER2-positive and ER/PR negative, with axillary sampling indicating 5 positive lymph nodes and a chest X-ray showing metastatic lesions. The patient has not yet received chemotherapy for her metastatic breast cancer and is a candidate for tumor resection.\n\nThe clinical trial in question is seeking female patients with histologically/cytologically proven metastatic breast carcinoma who have not received prior chemotherapy for metastatic breast cancer. Adequate bone marrow, liver, and renal function are also required for inclusion, but the patient note does not provide specifics on the patient's bone marrow, liver, and renal function.\n\nHowever, based on the information given, the patient appears to meet the primary inclusion criteria:\n\n- Female patient: Yes, the patient is a postmenopausal woman.\n- Histologically/cytologically proven metastatic breast carcinoma: Yes, the patient has cytologically confirmed metastatic breast cancer.\n- Not received prior chemotherapy for metastatic breast cancer: There is no indication of prior chemotherapy for metastatic breast cancer mentioned in the patient note.\n\nSince the patient note does not provide information regarding the patient's bone marrow, liver, and renal function, we cannot fully ascertain her eligibility. Nonetheless, the patient meets the basic disease-specific criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "23": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial. \n\nLet's examine the inclusion criteria against the patient's information:\n\n1. Histologically or cytologically confirmed breast cancer: The patient has cytologically confirmed breast cancer.\n2. Locally advanced disease (stage II or III): The patient has metastatic lesions indicated by a CXR, which suggests that the cancer may be beyond stage III. However, the trial does not explicitly exclude stage IV patients.\n3. Not amenable to breast-conserving therapy at the time of diagnosis: The patient is a candidate for tumor resection, which suggests that the cancer may be amenable to breast-conserving therapy, but this is not explicitly stated.\n4. Measurable disease meeting the specified criteria: The patient has a 3 cm invasive ductal breast carcinoma, which meets the measurable disease criteria.\n5. No evidence of disease outside the breast or chest wall except ipsilateral axillary lymph nodes: The patient has metastatic lesions, which indicates evidence of disease outside the breast or chest wall. This would exclude the patient from the trial.\n6. Hormone receptor status: The tumor is HER2-positive and ER/PR negative. The trial requires estrogen and/or progesterone receptor positivity, which the patient does not have.\n7. Age: The patient is 45 years old and postmenopausal, which fits the age criterion.\n8. Sex: The patient is female.\n9. Menopausal status: The patient is postmenopausal.\n10. Performance status: Not specified for the patient, but there is no indication that the patient would not meet an ECOG 0-3 performance status.\n11. Hematopoietic, hepatic, and renal function: Not specified for the patient, but there is no indication of issues with these functions.\n12. No other prior or concurrent cancer except for certain exceptions: The patient note does not indicate any other prior or concurrent cancer.\n13. No prior biologic therapy, chemotherapy, endocrine therapy, or radiotherapy for breast cancer: The patient is indicated to be a candidate for surgery prior to chemotherapy, suggesting no prior chemotherapy for breast cancer has been administered.\n\nBased on the patient's cancer being metastatic (outside the breast or chest wall) and hormone receptor status being HER2-positive and ER/PR negative, the patient does not meet the inclusion criteria for the clinical trial. \n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "24": {
        "output": "To determine the patient's eligibility for the described clinical trial, we must evaluate the patient's information against the inclusion and exclusion criteria provided.\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma, HER2-positive, and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present in CXR\n- Candidate for tumor resection, agrees to undergo surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria Evaluation:\n- Patients must be greater than or equal to 18 years of age. (Patient is 45, meets criteria)\n- The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Not enough information to determine)\n- The interval between the last surgery for breast cancer treatment and randomization must be no more than 84 days. (Patient agrees to surgery prior to chemotherapy, meets criteria)\n- The tumor must be invasive adenocarcinoma on histologic examination. (Patient has invasive ductal carcinoma, meets criteria)\n- The primary tumor must be T1-3 by clinical and pathologic evaluation. (Patient's tumor is 3 cm, likely T1 or T2, meets criteria)\n- Lymph nodes obtained from all axillary staging procedures must be pN0. (Patient has 5 positive lymph nodes, does not meet criteria)\n- Patients must have no clinical or radiologic evidence of metastatic disease. (Patient has metastatic lesions, does not meet criteria)\n- The patient's menopausal status must be determined prior to randomization. Postmenopausal women are eligible. (Patient is postmenopausal, meets criteria)\n\nClinical Trial Exclusion Criteria Evaluation:\n- Male patients are not eligible for this study. (Patient is female, not excluded)\n- Pure tubular or mucinous adenocarcinomas. (Not the patient's diagnosis, not excluded)\n- Bilateral malignancy or a mass in the opposite breast suspicious for malignancy unless biopsied as benign. (No information provided, not excluded)\n- Primary tumor staged as T4. (Patient's tumor likely T1 or T2, not excluded)\n- Suspicious palpable nodes outside of the axilla or previous breast cancer. (Patient has positive lymph nodes but no mention of previous breast cancer, not excluded based on available info)\n- Treatment including certain therapies prior to randomization. (No information on previous treatments other than planned surgery, not excluded based on available info)\n- Prior anthracycline therapy for any malignancy. (No information provided, not excluded)\n- Cardiac disease that would preclude the use of anthracyclines. (No information provided, not excluded)\n- Non-malignant systemic disease that would preclude treatment options or follow-up. (No information provided, not excluded)\n- Pregnancy or lactation at the time of proposed randomization. (No information provided, not excluded)\n- Concurrent treatment with investigational agents. (No information provided, not excluded)\n- Psychiatric or addictive disorders or other conditions that would preclude meeting study requirements. (No information provided, not excluded)\n\nBased on the information provided, the patient does not meet the inclusion criteria due to the presence of positive lymph nodes and evidence of metastatic disease. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "25": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes in axillary sampling\n- Metastatic lesions evident in CXR\n- Planned for tumor resection before chemotherapy\n\nClinical trial:\n- Title: Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer\n- Inclusion criteria:\n  - Clinical stage I lung cancer\n  - Surgical resection planned\n  - Histologic confirmation of lung cancer not required\n  - Preoperative mediastinoscopy allowed\n  - No prior therapy for lung cancer diagnosis\n  - No prior mediastinal radiation therapy\n  - Age \u2265 18 years\n  - ECOG performance status: 0-2\n\nEligibility Assessment:\n- The trial is for patients with non-small cell lung cancer, whereas the patient has breast cancer. Therefore, the patient does not meet the disease-specific criteria.\n- The patient is of appropriate age (\u226518 years).\n- There's no mention of the patient's ECOG performance status.\n\nSince the patient does not have the specific type of cancer (non-small cell lung cancer) required for the clinical trial, she is not eligible to participate in this trial. Other details, such as ECOG performance status, are not relevant in this case because the primary disease criteria are not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "26": {
        "output": "The patient note describes a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The patient has invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative, with metastatic lesions and positive lymph nodes.\n\nComparing this patient note with the inclusion criteria of the clinical trial:\n\n1. Patients must be \u226518 years old. \u2013 The patient is 45 years old, which meets this criterion.\n2. Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter. \u2013 The patient is a candidate for tumor resection, but it has not been stated that it has been completed.\n3. Patients must be able to have catheters placed within 14 days of tumor resection \u2013 The patient agrees to tumor resection prior to chemotherapy, but there is no information about catheter placement or the timing of the surgery.\n4. Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA. \u2013 The patient has breast cancer, not glioma.\n5. Patients must be in adequate general condition and meet certain performance and hematologic criteria. \u2013 There is insufficient information about the patient's Karnofsky Performance Scale score, hematologic status, or other health conditions mentioned in the inclusion criteria.\n6. Female patients must not be pregnant or breast-feeding \u2013 The patient is postmenopausal, which implies she is not pregnant or breast-feeding.\n7. Patients must practice an effective method of birth control during the study and for 60 days beyond the last day of infusion \u2013 There is no information provided regarding this, but being postmenopausal usually means the patient is not fertile.\n8. Patients must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure \u2013 There is no information provided regarding this.\n\nBased on the provided patient note and the clinical trial's inclusion criteria, the patient does not have malignant glioma, which is a key requirement for participation in the study. The patient has breast cancer, which is not the target disease for the trial. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "27": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer,\" we need to assess the provided patient information against the inclusion and exclusion criteria of the trial.\n\nFrom the patient note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There is evidence of metastatic lesions on CXR.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nNow, comparing this information to the trial criteria:\n\nInclusion Criteria Assessment:\n1. The patient must consent to participate in the study (not specified, but she agrees to surgery, so likely to consent).\n2. Life expectancy of at least 10 years and Zubrod performance status of 0 or 1 (not specified).\n3. Interval between last surgery for breast cancer staging or treatment and randomization no more than 84 days (not yet undergone surgery, so potentially meets this criterion).\n4. The tumor must be invasive carcinoma of the breast (meets this criterion).\n5. All the following staging criteria must be met (meets clinical T1-3 and pathologic pN1).\n6. ER analysis performed, and if negative, then PgR analysis (ER/PR status is negative, so this is met).\n7. No clinical or radiologic evidence of metastatic disease (does not meet this criterion due to metastatic lesions on CXR).\n8. Postoperative AGC and platelet count requirements (not applicable yet; surgery not performed).\n9. Adequate hepatic function (not specified).\n10. History and physical exam, EKG, and imaging of the chest within the past 3 months, and bilateral mammogram within the past 6 months (not specified).\n11. LVEF greater than or equal to LLN (not specified).\n12. No history of non-breast malignancies within 5 years (not specified, but nothing indicated).\n13. Special conditions for lumpectomy or mastectomy patients (not yet undergone surgery).\n14. No clinical or radiologic evidence of metastatic disease (does not meet this criterion due to metastatic lesions on CXR).\n\nExclusion Criteria Assessment:\n1. Male patients are not eligible (patient is female, so this is met).\n2. HER2-positive tumors (patient's tumor is HER2-positive, so she does not meet this criterion).\n3. Other specified ineligibility factors (not enough information to assess others, but HER2 status is enough for exclusion).\n\nBased on the available information, especially the presence of metastatic lesions on CXR and the fact that the tumor is HER2-positive, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "28": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\nThe patient:\n- Is a 45-year-old postmenopausal woman, which satisfies the trial's age and sex requirements.\n- Has a diagnosis of invasive ductal breast carcinoma larger than 3 cm, which meets the trial's disease characteristics.\n- The tumor is HER2-positive, which is allowed as per the trial's inclusion criteria.\n- Has positive axillary lymph nodes, which the trial allows.\n\nHowever, the patient note also mentions:\n- The patient has metastatic lesions as shown by a CXR, which indicates distant metastases.\n\nThe trial excludes individuals who have:\n- Distant metastases.\n\nSince the patient has distant metastases, she does not meet the trial's inclusion criteria that specifically exclude individuals with distant metastases. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "29": {
        "output": "",
        "label": 0
    },
    "30": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The inclusion criteria for the clinical trial are as follows:\n\n1. **Histological or cytological diagnoses of breast cancer, with metastases.**\n   - The patient has invasive ductal breast carcinoma with metastatic lesions noted on CXR.\n   \n2. **Metastatic lesions should not be curable with surgery or radiotherapy.**\n   - The presence of metastatic lesions suggests that the cancer is not curable with surgery or radiotherapy.\n   \n3. **Women of age > 18.**\n   - The patient is 45 years old.\n   \n4. **To have received a previous treatment with anthracyclines and taxanes.**\n   - There is no information provided about previous treatments; thus, it cannot be confirmed if she meets this criterion.\n   \n5. **A maximum of 2 previous chemotherapy treatment lines for metastatic disease.**\n   - Again, there is no information on the number of chemotherapy treatments she has received.\n   \n6. **Previous radiotherapy is allowed, whenever the radiated area is not the only disease location.**\n   - There is no information about any previous radiotherapy.\n   \n7. **At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities.**\n   - Since there is no information about the timing of previous treatments, this criterion cannot be assessed.\n   \n8. **Performance status < 2 in World Health Organization (WHO) scale.**\n   - The patient's performance status is not mentioned.\n   \n9. **Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.**\n   - The patient has clinically confirmed and measurable metastatic breast cancer.\n   \n10. **Life expectancy of at least 12 weeks.**\n   - Life expectancy is not provided in the patient note.\n   \n11. **Patients able to comply and to receive an adequate follow-up.**\n   - The patient agrees to tumor resection, which suggests willingness to comply with treatment, but this does not confirm her ability to comply with study follow-up specifically.\n   \n12. **Adequate bone marrow function: neutrophils \u2265 2 x 10^9/L; platelets \u2265 100 x 10^9/L; hemoglobin \u2265 100 g/L.**\n    - The patient's blood counts are not provided.\n   \n13. **Calcium within normal limits.**\n    - Calcium levels are not mentioned.\n   \n14. **Premenopausal women must adopt an adequate contraceptive method during the study and up to 3 months after treatment finalization.**\n    - The patient is postmenopausal, so this criterion does not apply.\n\nGiven the information provided, the patient meets some of the inclusion criteria, such as age and the presence of metastatic breast cancer. However, there is insufficient information to determine if she meets all the inclusion criteria (previous treatments, performance status, bone marrow function, etc.). Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "31": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria:\n- Clinically node negative operable breast cancer.\n- No prior incision or excision biopsy.\n\nAssessment:\n- The patient has operable breast cancer, which is a potential match for the trial.\n- However, the trial requires participants to be clinically node negative, meaning no lymph nodes are positive for cancer upon clinical examination.\n- The patient has 5 positive lymph nodes, as confirmed by axillary sampling.\n- Therefore, the patient does not meet the \"clinically node negative\" requirement.\n\nGiven that the patient has positive lymph nodes, she does not meet the inclusion criteria of being clinically node negative. Consequently, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "32": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial.\n\nPatient note key points:\n\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR showed metastatic lesions\n- No mention of bone lesions or their symptoms\n- Candidate for tumor resection prior to chemotherapy\n- No information on prior chemotherapy or hormone therapy for metastatic disease\n- No information on renal function or serum calcium levels\n- Performance status is not mentioned\n- No mention of current pregnancy status, but it is stated she is not sexually active\n\nClinical trial inclusion criteria:\n\n- Age \u2265 18 years old (patient is 45, meets this criterion)\n- Metastatic breast cancer patients with lytic, sclerotic, or mixed bone lesions (patient note does not mention bone lesions)\n- Non-symptomatic bone lesions (cannot be assessed without information on the presence of bone lesions)\n- A maximum of two chemotherapy lines for metastatic disease (not specified in the patient note)\n- A maximum of two hormone therapy lines for metastatic disease (not specified in the patient note)\n- Normal, minimally altered renal function (not specified in the patient note)\n- Normal serum calcium levels (not specified in the patient note)\n- Performance status 0,1 (WHO) (not specified in the patient note)\n- Negative pregnancy test before study recruitment (likely not pregnant as per patient note, but not confirmed)\n\nThe patient note does not provide sufficient information to determine the patient's eligibility based on several key inclusion criteria. Specifically, we do not have information about the presence of bone lesions, prior treatments for metastatic disease, renal function, serum calcium levels, performance status, or a confirmed pregnancy test.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "33": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed HER2-positive and ER/PR-negative invasive ductal breast carcinoma, with metastatic lesions and positive lymph nodes. The patient has not yet undergone chemotherapy but is a candidate for tumor resection.\n\nThe clinical trial is investigating the benefit of adding Trastuzumab to second-line chemotherapy in breast cancer patients who have been previously treated with Trastuzumab. The patient in question has HER2 positive breast cancer, which fits the criteria. However, the trial requires the patient to have non-operable locally advanced or metastatic disease previously treated with Trastuzumab and taxanes. The patient note does not indicate any previous treatment with Trastuzumab and taxanes, which is an essential inclusion criterion for this trial. Additionally, there is no information on whether the patient has measurable or non-measurable disease as per RECIST, the performance status, or other specific health criteria mentioned in the inclusion criteria.\n\nBased on the provided patient note and the inclusion criteria of the clinical trial, there is not enough information to determine if the patient has been previously treated with Trastuzumab and taxanes or meets other specific health criteria. Thus, the patient's trial-level eligibility cannot be determined as either eligible or excluded due to a lack of information on key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "34": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility.\n\nThe patient:\n- Is a 45-year-old postmenopausal woman.\n- Has cytologically confirmed breast cancer.\n- Has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Has metastatic lesions present on CXR.\n- Is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nThe inclusion criteria for the clinical trial:\n- Written informed consent.\n- Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3).\n- Tumors must be HER2 negative.\n- Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks; in patients receiving adjuvant radiotherapy, time window allowed between last session and randomization is 4 weeks.\n- Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and DCIS are required.\n- Node negative patients with tumor size > 2 cm or positive axillary lymph nodes defined as at least 1 out of 6 nodes with presence of disease.\n- Negative status of HER2 in primary tumor, known before randomization.\n- Adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines and/or taxanes.\n- Age >= 18 and <= 70 years old.\n- Performance status (Karnofsky index) >= 80.\n- Specific laboratory results within normal ranges.\n- No evidence of metastatic disease.\n- Able to comply with treatment and study follow-up.\n- Negative pregnancy test for women of childbearing potential.\n\nThe patient does not meet the following inclusion criteria:\n- The patient's tumor is HER2-positive, whereas the trial requires the tumor to be HER2 negative.\n- The patient presents evidence of metastatic disease, which is excluded by the trial criteria.\n\nGiven this information, the patient is excluded from the trial due to having a HER2-positive tumor and evidence of metastatic disease, both of which are in direct conflict with the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "35": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer,\" we need to match the patient's characteristics and medical history with the inclusion criteria provided.\n\nBased on the patient note, here's what we know about the patient:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- She has metastatic breast cancer with a positive core biopsy and positive axillary lymph nodes.\n- She is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n- It is not mentioned that she has had any prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer.\n\nNow, let's compare this information with the inclusion criteria:\n\n1. Female patient, postmenopausal - The patient is postmenopausal.\n2. Histologically or cytologically proven adenocarcinoma of the breast - The patient has cytologically confirmed breast cancer.\n3. HER2-positive disease - The patient has HER2-positive disease.\n4. ER-positive and/or PR-positive disease - The patient does NOT meet this criterion since she has ER/PR negative disease.\n5. ECOG performance status 0-2 - Not mentioned in the patient note.\n6. Life expectancy > 24 weeks - Not mentioned in the patient note, but typically assumed in a candidate for tumor resection.\n7. Left ventricular ejection fraction > lower limit of normal - Not mentioned in the patient note.\n8. No prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer - The patient note does not mention prior therapy, so we assume she meets this criterion.\n9. Prior adjuvant Herceptin permitted - Not mentioned in the patient note.\n10. At least 1 month since prior surgery, radiotherapy, or endocrine therapy, with complete recovery from these interventions - The patient is planned for surgery but has not yet undergone it.\n11. Patients must have ended any hormone replacement therapy at least 1 month prior to receiving the first dose of trial therapy - Not mentioned in the patient note.\n12. Patients treated with bisphosphonates may enroll - Not mentioned in the patient note.\n13. Patient is accessible and willing to comply with treatment and follow-up - The patient agrees to tumor resection, implying willingness to comply with treatment.\n14. Patient is willing to provide written informed consent - Not mentioned in the patient note, but typically assumed if the patient is considering clinical trial participation.\n15. Required laboratory values - Not mentioned in the patient note.\n\nBased on the information available, the patient does not meet the inclusion criterion of having ER-positive and/or PR-positive disease since her tumor is ER/PR negative. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "36": {
        "output": "",
        "label": 2
    },
    "37": {
        "output": "Based on the provided patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, with metastatic lesions and positive lymph nodes. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nThe clinical trial in question is looking at the correlation between tumor angiogenesis and the effect of radiation therapy in cervical cancer patients. The inclusion criteria for the clinical trial specifically states that it is for \"cervical cancer patients receiving radiotherapy or chemo-radiotherapy.\"\n\nGiven that the patient in the note has breast cancer, not cervical cancer, she does not meet the disease-specific inclusion criteria for the clinical trial. Therefore, the patient is not eligible to participate in this cervical cancer-focused clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "38": {
        "output": "Given Patient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions observed on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Women >= 40 with invasive ductal carcinoma or ductal carcinoma in situ\n- Patient chooses lumpectomy rather than mastectomy as treatment for breast cancer\n- Tumor < 2.5 cm in size, 2 mm margin of normal breast tissue between cancer and edge of specimen\n\nThe patient is a 45-year-old woman with invasive ductal breast carcinoma, which aligns with the first inclusion criterion of the clinical trial regarding the patient's sex and type of cancer. However, her tumor size is 3 cm, which exceeds the specified inclusion criterion of the clinical trial that requires the tumor to be less than 2.5 cm in size. Despite meeting the age and diagnosis criteria, the patient's tumor size makes her ineligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "39": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2,\" we need to compare the patient's information to the inclusion criteria provided.\n\nBased on the patient note provided, here is the relevant information:\n\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer, which is invasive ductal carcinoma.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions present as indicated by a remarkable CXR.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n- There is no mention of the patient's ECOG performance status, but given she is a candidate for surgery, it may be assumed to be relatively good (<2).\n- There is no mention of other serious illnesses or medical conditions.\n- There is no mention of CNS metastases, and since it is stated that CXR was remarkable for metastatic lesions, it implies that metastases are not CNS.\n- There is no mention of rapidly progressive visceral metastases or an active concurrent infection.\n- There is no mention of current anti-cancer treatment, but she is a candidate for surgery and chemotherapy.\n- Previous therapies are not detailed, so we cannot confirm prior investigational biological agents or previous hormonal therapy.\n- There is no information about prior adjuvant and MBC chemotherapy or intervals since last chemotherapy administration.\n- There is no information on the cumulative dose of previous doxorubicin or epirubicin.\n- There is no mention of organ function tests, but we can assume they may be adequate given she is a candidate for surgery.\n- The tumor is HER2-positive.\n- There is no information on baseline LVEF.\n- There is no information on measurable disease according to RECIST criteria.\n- There is no information on pregnancy status or willingness to use birth control.\n- Psychological, familial, sociological or geographical conditions are not mentioned.\n- Informed consent is not mentioned, but it is typically obtained as part of the clinical trial process.\n\nGiven the information above, the patient seems to match many of the inclusion criteria, such as being a female over 18 years of age, having a histologically proven diagnosis of breast cancer with HER2-positive status, and having locally advanced/metastatic disease. \n\nHowever, some key pieces of information are missing to fully determine eligibility, such as:\n\n- ECOG performance status.\n- Detailed medical history regarding other serious illnesses or medical conditions.\n- Information on CNS metastases.\n- Information on current and past treatments, including chemotherapy intervals and prior use of investigational biological agents.\n- Lab results for organ function.\n- Baseline LVEF.\n- Measurable disease according to RECIST criteria.\n- Pregnancy status and willingness to use birth control.\n- Confirmation of informed consent.\n\nBecause of these missing pieces of information, we cannot definitively conclude that she is eligible for the trial. Therefore, the assessment of eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "40": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we need to assess the patient's eligibility for the trial:\n\nPatient information:\n- Age: 45 years old (meets age criterion of \u2265 18 years)\n- Diagnosis: Cytologically confirmed breast cancer (meets criterion of solid tumor treatment)\n- Treatment: Candidate for tumor resection and agrees to chemotherapy (meets criterion of planned chemotherapy cycles)\n- Additional information: The patient is using multivitamins and iron supplements, which could be related to managing anemia. However, the note does not specify the patient's hemoglobin levels to determine if they fall within the moderate anemia range required by the study.\n\nClinical trial inclusion criteria:\n- Age \u2265 18 years (patient meets this criterion)\n- Well-informed written consent, signed by the patient (not specified but assumed that patient can provide if eligible)\n- Patient picked up for solid tumor treatment, with or without metastasis (patient meets this criterion with breast cancer and metastatic lesions)\n- Patient revealing, before or during chemotherapy, a moderate anemia, that means: Women: 9<Hb<11 g/dl (not specified in the patient note)\n- Patient for whom at least four chemotherapy cycles are planned (eight in case of weekly chemotherapy) after inclusion in the study (the patient agrees to chemotherapy but the number of planned cycles is not specified)\n- Patients with life expectancy higher than three months (not specified but given the planned treatment, it is likely assumed)\n- Patient with general conditions compatible with the study's follow-up (not specified)\n\nThe patient note does not provide sufficient information regarding the patient's hemoglobin levels, the specific number of planned chemotherapy cycles, life expectancy, or whether the patient's general condition is compatible with the study's follow-up. Therefore, based on the available information, the patient's eligibility for this clinical trial cannot be confirmed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "41": {
        "output": "The patient in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which fits the criterion of a tumor stage T1 or T2 lesion being less than 3 cm. The patient also has positive lymph nodes, with axillary sampling revealing 5 positive nodes, which fits the N1 criterion of having 1-3 positive nodes. There is no mention of extracapsular extension, which meets the inclusion criteria of N0 or N1 without extracapsular extension. The patient is a candidate for tumor resection and agrees to undergo it prior to chemotherapy, which is in line with the intention of the trial to treat the tumor bed with radiation.\n\nThe clinical trial is investigating the use of Multi-catheter High Dose Rate (HDR) Breast Brachytherapy, specifically for patients with invasive breast cancer or DCIS, where the tumor stage is Tis, T1, or T2 if the lesion is less than 3 cm, and N0 or N1 if there are 1-3 positive nodes with no extracapsular extension. \n\nBased on the information provided, the patient meets the inclusion criteria for the clinical trial:\n\n- The patient has invasive breast cancer.\n- The tumor is T2 since it's a 3 cm lesion.\n- The patient has N1 disease (1-3 positive lymph nodes) with no mention of extracapsular extension.\n\nGiven this information, the patient appears to be eligible for the trial as there is no information suggesting that the exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "42": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The biopsy revealed invasive ductal breast carcinoma which is HER2-positive and ER/PR negative.\n- She has metastatic lesions as indicated by a CXR.\n- The patient is a candidate for tumor resection and agrees to undergo surgery prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Histologically confirmed invasive breast cancer by fine needle aspiration or biopsy: The patient has invasive ductal breast carcinoma confirmed by core biopsy, which meets this criterion.\n- Locally advanced or early metastatic disease: The patient has metastatic lesions, which meets this criterion.\n- Clinically or radiographically measurable disease: The tumor is measurable, which meets this criterion.\n- Planning to receive neoadjuvant chemotherapy for locally advanced or early metastatic disease: The patient agrees to undergo surgery prior to chemotherapy, which implies she is planning to receive neoadjuvant chemotherapy.\n- No prior chemotherapy for this malignancy: The patient note does not indicate any prior chemotherapy, meeting this criterion.\n\nThe patient meets all the inclusion criteria stated for the clinical trial. There is no mention of any exclusion criteria in the clinical trial information provided. Therefore, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "43": {
        "output": "",
        "label": 1
    },
    "44": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's compare the information step by step:\n\nPatient's characteristics:\n- The patient is a 45-year-old postmenopausal woman, which matches the age requirement of the clinical trial (18 years or older).\n- The patient has cytologically confirmed breast cancer, which is necessary for the trial (histologically or cytologically confirmed locally advanced or metastatic breast cancer).\n- The patient has a tumor that is HER2-positive and ER/PR negative, while the trial is looking for premenopausal patients with advanced ER and PR + breast cancer. This does not align with the patient's tumor profile.\n- The patient is a candidate for tumor resection before chemotherapy, which could imply that curative treatment is available, potentially conflicting with the trial's criterion of \"no curative treatment available.\"\n\nClinical trial's inclusion criteria:\n- Signed informed consent.\n- Premenopausal women 18 years or older.\n- Histologically or cytologically confirmed locally advanced or metastatic breast cancer.\n- Suitable for endocrine treatment.\n- No curative treatment available.\n- One or more measurable lesions.\n- Life expectancy more than 6 months.\n- Normal biological parameters.\n\nGiven that the trial specifically requires premenopausal women with ER and PR + breast cancer, and the patient is postmenopausal with HER2-positive and ER/PR-negative breast cancer, the patient does not meet the necessary inclusion criteria for this specific trial. Additionally, the patient is planning to undergo tumor resection which may suggest the availability of curative treatment, another mismatch with the trial criteria.\n\nTherefore, the patient does not qualify for the trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "45": {
        "output": "The patient described is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the inclusion criteria of the clinical trial, patients with pathological diagnoses of breast cancer are eligible.\n\nLet's break down the inclusion criteria and see if the patient matches:\n\n1. Patients with pathological diagnoses of breast, lung, and ovarian adenocarcinomas and soft tissue sarcoma.\n   - The patient has invasive ductal breast carcinoma, which fits the pathological diagnosis of breast cancer.\n\n2. Patients with de novo malignancies and no previous chemotherapy.\n   - The patient note does not mention any prior chemotherapy, suggesting the patient has a de novo malignancy.\n\n3. Patients with advanced refractory malignancies who received no more than 2 standard chemotherapy treatment protocols.\n   - As there is no mention of previous chemotherapy, this criterion is not applicable.\n\n4. Patients of any age group.\n   - The patient is 45 years old, fitting this criterion.\n\n5. Patients must have tumor which is accessible and agree to undergo biopsies, or drainage of effusions.\n   - The patient is a candidate for tumor resection, which implies that the tumor is accessible. She agrees to undergo surgery, which can be seen as a willingness to undergo procedures to treat her condition.\n\n6. Patients for whom chemotherapy is a treatment option.\n   - The patient has not yet received chemotherapy but is a candidate for it post-surgery.\n\nBased on the above, the patient matches all the inclusion criteria for the clinical trial. There are no exclusion criteria mentioned, so we cannot determine if the patient would be excluded for any reason not covered in the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "46": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria set out by the trial.\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer (invasive ductal carcinoma)\n- HER2-positive and ER/PR-negative\n- 5 positive lymph nodes and metastatic lesions on CXR\n- Candidate for tumor resection, agreeing to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female, postmenopausal\n- Histologically confirmed breast cancer (DCIS or invasive carcinoma, Stage I-III disease)\n- Must have undergone breast cancer surgery within the past 6 months\n- Estrogen and/or progesterone receptor-positive tumor\n- No prior or concurrent adjuvant chemotherapy for breast cancer\n- No prior aromatase inhibitor, tamoxifen, or hormone replacement therapy (at least 6 weeks since any such prior therapy)\n- No prior radiation therapy or mastectomy for the breast cancer being studied\n\nAssessment:\n- The patient is postmenopausal and female, which fits the trial's patient characteristics.\n- The patient has confirmed invasive ductal breast carcinoma, which meets the trial's disease characteristics.\n- However, the trial requires the tumor to be estrogen and/or progesterone receptor-positive, and the patient's tumor is ER/PR-negative. This does not fit the hormone receptor status requirement of the trial.\n- The patient is a candidate for tumor resection but has not yet undergone surgery. The trial requires that the patient must have undergone surgery within the past 6 months.\n\nBased on these points, the patient does not meet all of the inclusion criteria due to the hormone receptor status and the fact that she has not yet undergone breast cancer surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "47": {
        "output": "The patient described in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer that is HER2-positive and ER/PR negative. She has a history of metastatic lesions and is a candidate for tumor resection before chemotherapy.\n\nComparing this patient's profile to the inclusion criteria of the clinical trial titled \"Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer,\" we observe the following:\n\n1. The clinical trial is looking for patients with recurrent or metastatic breast cancer, which matches the patient's condition of metastatic lesions.\n2. However, the inclusion criteria specify that the patient's cancer must be triple receptor negative (ER, PR, and HER2 negative). The patient's tumor is reported to be HER2-positive, which does not match the requirement for triple negative status.\n3. The inclusion criteria also require prior treatment with an anthracycline and a taxane, which is not mentioned in the patient's note.\n4. There is no information about relapse following adjuvant chemotherapy within 6 months of last treatment or treatment regimens for advanced disease in the patient's note.\n\nGiven the information provided, the patient does not meet the requirement for the receptor status, as her cancer is not triple receptor negative due to HER2 positivity. Therefore, she is not eligible for this clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "48": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Women or men > 18 years old with histologically confirmed, by needle core biopsy (not FNA), locally advanced or inflammatory breast cancer.\n- Tumor classification must fit into one of the following: T2 lesion initially resectable only through mastectomy; T3 N0-N2; T4 any N; or any T with N2 or N3 clinical evidence of disease.\n- Measurable disease defined as a breast lesion > 2 cm or with fixed or marked ipsilateral axillary nodes and/or ipsilateral internal mammary nodes.\n- Pre- and Post-menopausal female and male patients are eligible.\n- Negative scans for metastatic bone disease and CAT scan of chest and abdomen.\n\nThe patient does have a confirmed invasive ductal breast carcinoma which is > 2 cm and has positive lymph nodes, meeting part of the inclusion criteria regarding the disease's characteristics and extent. However, the patient's CXR indicating metastatic lesions is a disqualifying factor because the trial requires a negative scan for metastatic disease. The inclusion criteria specify that patients must have a bone scan and CAT scan of chest and abdomen negative for metastatic disease, which the patient does not have as there is evidence of metastatic lesions.\n\nTherefore, the patient is not eligible for the clinical trial due to the presence of metastatic lesions, which disqualify her based on the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "49": {
        "output": "To determine the patient's eligibility for the clinical trial, we must assess the patient's characteristics against the inclusion criteria stated in the clinical trial. Here is the breakdown:\n\nPatient Characteristics:\n- The patient is a 45-year-old postmenopausal woman.\n- Has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Has metastatic lesions (CXR).\n- She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of breast cancer (confirmed).\n- T2-T4c, any N, M0 disease (patient has metastatic lesions, suggesting M1 disease).\n- The primary tumor must be palpable and measure > 2 cm in at least one dimension (confirmed).\n- Must agree to undergo mastectomy or lumpectomy after neoadjuvant aromatase inhibitor therapy (agreed).\n- No inflammatory breast cancer (no information suggesting this in the patient note).\n- No distant metastasis (patient has distant metastasis).\n- Isolated ipsilateral supraclavicular node involvement allowed (not mentioned in the patient note).\n- Must have estrogen receptor (ER) positive tumor with an Allred score of 6, 7, or 8 (patient has ER/PR negative tumor).\n- Postmenopausal status verified (confirmed).\n\nBased on the available information, the patient does not meet all the needed inclusion criteria for the clinical trial. Specifically, the patient has distant metastasis (M1), and the tumor is ER/PR negative, which does not meet the requirement for an ER-positive tumor with an Allred score of 6, 7, or 8.\n\nGiven these discrepancies, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "50": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, here is the assessment:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- She is a candidate for tumor resection and agrees to it prior to chemotherapy.\n- There is no indication that the patient has already undergone chemotherapy or radiation therapy, nor is there any mention of fatigue symptoms or their duration.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is seeking women who have moderate to severe fatigue for more than 6 months after their last chemotherapy or radiation treatment.\n- They should be more than 5 years from diagnosis.\n\nSince the patient is about to undergo chemotherapy, she would not meet the inclusion criteria of having had chemotherapy or radiation therapy and experiencing fatigue for more than 6 months after treatment. Additionally, the patient has not been indicated to be 5 years from diagnosis.\n\nTherefore, the patient does not have sufficient information available in the note to qualify for the trial, and the inclusion criteria clearly do not apply to her current situation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "51": {
        "output": "Given the patient note and the clinical trial information:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Chest X-Ray (CXR) showed metastatic lesions\n- Candidate for tumor resection, agreeing to undergo the procedure prior to chemotherapy\n\nClinical Trial:\n- Title: Detection of Genetic Markers of Lung Cancer\n- Inclusion Criteria:\n  - Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma, or a radiographic lesion highly suspicious for malignancy\n  - Written informed consent\n  - Must be scheduled for a biopsy or surgical resection\n\nThe patient in the note has breast cancer with metastatic lesions as observed on CXR. The clinical trial is specifically for lung cancer or lung metastases from a primary site other than the lung. Since the patient has breast cancer, not lung cancer, she does not meet the inclusion criteria for the lung cancer genetic markers study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "52": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman (meets age and menopausal status criteria)\n- Histologically confirmed breast cancer (meets disease characteristic)\n- Disease is not confined to the breast and axillary nodes as there are metastatic lesions (does not meet disease characteristic of being confined to the breast and axillary nodes without detected masses elsewhere)\n- The patient has positive lymph nodes and metastatic lesions, which suggests the disease may not be resected completely (potentially not meeting the criteria of resected disease with negative margins)\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy (does not clearly state whether surgery has already occurred, and if so, within the 16-week window)\n- No other malignancy within the past 5 years except for the conditions listed is mentioned (meets criteria if assuming no other malignancy)\n\nThe patient does not meet the criteria of having disease confined to the breast and axillary nodes as they have metastatic lesions, which is a clear exclusion based on the trial's inclusion criteria. Additionally, the status of tumor resection surgery and whether it occurred within the last 16 weeks is unclear, but given the presence of metastatic disease, this point may be moot for eligibility.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided information. The correct assessment would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "53": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the eligibility of the patient for the trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Diagnosed with HER2-positive and ER/PR-negative invasive ductal breast carcinoma\n- Tumor in the left upper outer quadrant, 3 cm in size\n- 5 positive lymph nodes, metastatic lesions present on CXR (presumably in the lungs)\n- Non-smoker, non-alcoholic, not sexually active, no children\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Female patient (matches)\n- Diagnosis of stage IIB HER2/neu-expressing breast cancer 6\u00bd years ago (not specified in patient note)\n- Received a T-cell-depleted allogeneic SCT from a 6/6 HLA-matched sibling donor for refractory metastatic breast cancer (not specified in patient note)\n- Developed pulmonary metastases during adjuvant chemotherapy following modified radical mastectomy (not specified in patient note)\n- Pulmonary metastases progressed after prior allogeneic SCT (not specified in patient note)\n- Responded to prior allogeneic lymphocyte infusion, post-transplantation chemotherapy, and trastuzumab (not specified in patient note)\n- Disease limited to the thoracic cavity (patient has pulmonary metastases, which could be considered thoracic)\n- Operable tumor with at least 1 cm of surgically accessible lesion (patient is a candidate for tumor resection)\n- Preoperative risk assessment indicating \u2264 5% risk of mortality and < 15% risk of significant morbidity for pulmonary metastasectomy (not specified in patient note)\n- Enrolled on protocol CC# 00-C-0119 (not specified in patient note)\n- ECOG performance status 0-2 (not specified in patient note)\n- Life expectancy > 6 months (not specified in patient note)\n- Negative pregnancy test (assumed, but not specified)\n- Adequate pulmonary reserve (not specified in patient note)\n- Prior GVHD \u2264 grade 1 (not specified in patient note)\n- No concurrent GVHD (not specified in patient note)\n- No active infection nonresponsive to antimicrobial therapy (not specified in patient note)\n- No active psychiatric disorder (not specified in patient note)\n- At least 4 weeks since prior systemic immunosuppressive therapy (not specified in patient note)\n- At least 2 weeks since prior cytotoxic therapy and immunotherapy (patient agrees to surgery prior to chemotherapy, but timing is not specified)\n\nThe patient note does not provide sufficient information to determine if the patient meets many of the inclusion criteria, especially those related to previous treatments and conditions that are very specific to the clinical trial. Therefore, the patient cannot be deemed eligible based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "54": {
        "output": "Let's evaluate the patient's eligibility based on the provided clinical trial inclusion criteria:\n\n1. Has metastatic breast cancer with documented HER2- or HER2+ (IHC3+ or FISH+) disease\n   - The patient has HER2-positive breast cancer, which meets this criterion.\n\n2. Has measurable MBC, with at least 1 measurable lesion per RECIST criteria (see Section 10). Irradiated lesions cannot be used to assess response but can be used to assess progression.\n   - The patient has a 3 cm invasive ductal breast carcinoma, which is considered a measurable lesion.\n\n3. Has had no prior treatment with Doxil or carboplatin; may have had adjuvant Herceptin if treatment was completed more than 1 year prior to study\n   - The patient note does not mention any prior treatment with Doxil or carboplatin, so this criterion appears to be met.\n\n4. Has had no adjuvant chemotherapy within 1 year prior to study, but may have received prior anthracyclines as adjuvant chemotherapy\n   - The patient is a candidate for tumor resection prior to chemotherapy, which indicates no adjuvant chemotherapy has been administered yet.\n\n5. For taxane-pretreated patients (adjuvant or metastatic), has had no more than 1 prior chemotherapy regimen for MBC\n   - The patient has not had chemotherapy yet, so this criterion is met.\n\n6. For taxane-na\u00efve patients, has had no prior chemotherapy for MBC\n   - The patient has not had chemotherapy yet, so this criterion is met.\n\n7. Has had cumulative doses of < 300 mg/m2 prior doxorubicin or < 450 mg/m2 prior epirubicin\n   - There is no information regarding prior doxorubicin or epirubicin, but since chemotherapy has not been started, this criterion is likely met.\n\n8. Has normal cardiac function as evidenced by a LVEF within institutional normal limits by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO) may be used if MUGA is not available, but the same test must be used throughout the study to evaluate LVEF.\n   - There is no information on the patient's cardiac function, so this criterion cannot be confirmed.\n\n9. Has an ECOG Performance Status (PS) 0-2 (see Appendix I)\n   - The patient's ECOG Performance Status is not mentioned, so this criterion cannot be confirmed.\n\n10. Is a male or female greater than or equal to 18 years of age\n    - The patient is 45 years old, which meets this criterion.\n\n11. Laboratory Values - Please refer to protocol section 4.2 for specific laboratory values.\n    - Specific laboratory values are not provided in the patient note.\n\n12. Has a negative serum pregnancy test within 7 days prior to registration (woman of childbearing potential [WOCBP; not surgically sterilized and between menarche and 1 year postmenopause])\n    - The patient is postmenopausal, which meets this criterion.\n\n13. If fertile, patient (male or female) has agreed to use an acceptable method of birth control (eg, abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.\n    - As the patient is postmenopausal, this criterion is not applicable.\n\n14. Has signed a Patient Informed Consent Form\n    - There is no information on whether the patient has signed a consent form.\n\n15. Has signed a Patient Authorization Form (HIPAA Form)\n    - There is no information on whether the patient has signed an authorization form.\n\n16. Has a life expectancy of > 3 months\n    - There is no information provided about the patient's life expectancy.\n\nBased on the available information, the patient appears to meet most of the inclusion criteria for the clinical trial. However, there is insufficient information on some criteria (cardiac function, ECOG Performance Status, laboratory values, consent forms, and life expectancy) to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "55": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient has metastatic lesions evident on chest X-ray.\n- The patient is using multivitamins and iron supplements.\n- The patient is a candidate for tumor resection and agrees to undergo this procedure prior to chemotherapy.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy).\n- Approval and informed consent.\n\nThe patient's condition matches the clinical trial's inclusion criteria of having infiltrative breast cancer diagnosed pre-operatively by core biopsy. Since the patient agrees to tumor resection, which is a part of the treatment process, it can be assumed that the patient is willing to participate in the trial and would provide informed consent.\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria provided, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "56": {
        "output": "",
        "label": 0
    },
    "57": {
        "output": "To determine the patient's eligibility for the Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer clinical trial, we should compare the patient's characteristics and condition to the inclusion and exclusion criteria of the trial.\n\nPatient's Characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes identified through axillary sampling\n- Presence of metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast cancer\n- Histologically negative tumor margin 2 mm or more\n- Certain histologic variants permitted\n- Women age 70 or older with specific tumor characteristics are eligible\n- T1N0 (i+) tumors acceptable with conditions\n- Prior treatment with adjuvant chemotherapy allowed; hormonal therapy allowed\n- Radiation therapy timeline after surgery or chemotherapy\n- Age >= 18 years\n- ECOG Performance Status 0-2\n- Signed Informed Consent\n\nClinical Trial Exclusion Criteria Include:\n- Multicentric or multifocal IDC of the breast\n- Tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement\n- Lymphovascular invasion or EIC (Extensive Intraductal Component)\n- Certain histologic types of breast cancer\n- Insufficient resection margins\n- History of certain surgeries or medical conditions\n- Active secondary malignancy\n- Pregnancy\n\nAssessment:\n- The patient does not have Unicentric Stage I (T1 N0 M0) breast cancer as required by the trial due to the presence of positive lymph nodes and metastatic lesions (exclusion criteria: tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement).\n- The patient's age and gender meet the inclusion criteria, but the stage and extent of the breast cancer do not align with the study's requirements for early breast cancer.\n\nGiven these points, the patient does not meet the inclusion criteria for the trial due to her breast cancer stage and the presence of metastatic disease, which are explicit exclusion criteria for the trial. Therefore:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "58": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"AZD1152 in Patients With Advanced Solid Malignancies,\" we must compare the patient's characteristics with the trial's inclusion criteria.\n\nPatient's Characteristics:\n- Age: 45 years\n- Gender: Female\n- Medical condition: Cytologically confirmed breast cancer\n- Tumor characteristics: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Metastatic disease: Yes, metastatic lesions noted on CXR\n- Treatment: Candidate for tumor resection, agreeing to proceed prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n1. Histological or cytological confirmation of a solid, malignant tumour\n2. At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n\nComparison:\n1. The patient has a cytologically confirmed diagnosis of breast cancer, which is a solid, malignant tumor. This meets the first inclusion criterion.\n2. The presence of a 3 cm invasive ductal breast carcinoma and metastatic lesions indicates the patient has at least one measurable or non-measurable site of disease according to RECIST criteria, fulfilling the second inclusion criterion.\n\nSince the patient's characteristics align with the inclusion criteria of the clinical trial and no exclusion criteria are provided, the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "59": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient's characteristics with the inclusion criteria specified by the clinical trial. Here are the inclusion criteria for the trial:\n\n1. Histologically or cytologically confirmed adenocarcinoma of the breast and appropriate for treatment with Doxorubicin and Cyclophosphamide.\n2. Age > 18 years and <45 years.\n3. ECOG performance status of 0 to 2.\n4. Signed informed consent.\n5. Premenopausal: defined as regularly occurring menstrual cycles or serologic estradiol and FSH levels consistent with premenopausal status.\n\nNow, let's analyze the patient note:\n\n1. The patient has a cytologically confirmed breast cancer, which is appropriate for the trial.\n2. The patient is a 45-year-old, which makes her ineligible based on the age criterion, which requires participants to be under 45 years of age.\n3. There is no information provided about the patient's ECOG performance status, so we cannot determine eligibility based on this criterion.\n4. The patient agrees to tumor resection, which suggests she may be willing to sign informed consent, but there's no explicit mention of signed informed consent for the trial.\n5. The patient is described as postmenopausal, which contrasts with the requirement for premenopausal status as defined by the trial.\n\nGiven that the patient is 45 years old and postmenopausal, she does not meet the age and menopausal status inclusion criteria of the clinical trial. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "60": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria specified for the trial.\n\nHere are the relevant details from the patient note:\n- The patient is a 45-year-old postmenopausal woman, which meets the age requirement of \"Women >/= 18 years of age.\"\n- The patient has cytologically confirmed breast cancer with a core biopsy revealing invasive ductal breast carcinoma, which meets the \"Histologically proven breast cancer\" criterion.\n- The patient has axillary sampling with 5 positive lymph nodes, which meets the \"lymph node-positive (pN1-3)\" criterion.\n- The tumor is HER2-positive, which is allowed as \"HER2/neu positive or negative tumors are eligible.\"\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which aligns with the requirement for definitive breast surgery followed by study registration within < 60 days.\n\nHowever, the following information is missing from the patient's note to fully determine eligibility:\n- The interval between definitive breast surgery and study registration (must be < 60 days).\n- Margins of resected specimen need to be free from invasive adenocarcinoma and DCIS.\n- Normal cardiac function must be confirmed by LVEF or shortening fraction.\n- Hematology and hepatic function evaluation results.\n- Complete staging work-up to rule out metastatic disease.\n\nBased on the provided patient note, we do not have sufficient information about the completion of surgery, margins status, cardiac function, hematology and hepatic function evaluation results, and the complete staging work-up. Therefore, we cannot definitively include or exclude the patient from the trial at this point.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "61": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- Age: 45 years old (meets age-related inclusion criteria)\n- Diagnosis: Breast cancer (relevant to the trial's target disease)\n- Tumor specifics: HER2-positive and ER/PR negative (tumor over-expressing Her-2, which is relevant to the trial)\n- Disease status: Metastatic lesions present (evidence of metastatic disease)\n- Treatment history: Candidate for tumor resection and agrees to proceed prior to chemotherapy (has not received chemotherapy treatment in the advanced disease setting, which is relevant to the trial)\n\nClinical trial inclusion criteria:\n- Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease (patient has metastatic disease)\n- Tumors over-expressing Her-2 (patient's tumor is HER2-positive)\n- Candidate for treatment with docetaxel/trastuzumab (patient is a candidate for tumor resection and agrees to chemotherapy, which is likely to include docetaxel/trastuzumab)\n\nGiven this information, the patient appears to meet the inclusion criteria for the clinical trial as specified:\n\n- The patient's age is \u2265 18 years.\n- The patient has a diagnosis of breast cancer with metastatic disease, which is unresectable or locally recurrent.\n- The tumor is HER2-positive, hence over-expressing Her-2.\n- The patient has not received chemotherapy in the advanced disease setting and is a candidate for treatment that aligns with the trial's regimen (docetaxel/trastuzumab).\n\nThere is no mention of any exclusion criteria in the trial description, and the patient does not have any characteristics that would automatically exclude her from the trial based on the information provided.\n\nTherefore, the patient is eligible to participate in the clinical trial. \n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "62": {
        "output": "Based on the provided patient note and the clinical trial inclusion and exclusion criteria, let's assess the eligibility of the patient:\n\nPatient Note Analysis:\n1. The patient is a 45-year-old postmenopausal woman.\n2. She has cytologically confirmed breast cancer.\n3. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n4. The tumor is HER2-positive and ER/PR negative.\n5. Axillary sampling revealed 5 positive lymph nodes.\n6. CXR was remarkable for metastatic lesions.\n7. The patient is using multivitamins and iron supplements.\n8. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n1. Confirmed diagnosis of Breast Cancer with at least one breast cancer-related bone lesion.\n2. No treatment with bisphosphonates within 6 months prior to inclusion into the study.\n3. Good health status (ECOG Performance status 0-2).\n\nClinical Trial Exclusion Criteria:\n1. Patients who do not have at least one breast cancer-related bone lesion that is detectable on conventional radiographs of bone (plain film) at screening.\n2. Abnormal renal function.\n3. History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism.\n4. Pregnancy and lactation.\n5. Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction, implants).\n\nEligibility Assessment:\n- The patient has a confirmed diagnosis of breast cancer with metastatic lesions, which likely includes bone lesions.\n- There is no mention of bisphosphonate treatment within the last 6 months.\n- The patient's health status is not explicitly mentioned, but she is a candidate for tumor resection which suggests a reasonable health status.\n- There is no mention of exclusion criteria such as abnormal renal function, history of diseases with influence on bone metabolism, pregnancy, lactation, or current active dental problems.\n\nGiven this information, the patient appears to meet the inclusion criteria and none of the exclusion criteria are explicitly mentioned or implied in the patient note. Thus, the patient seems eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "63": {
        "output": "Assessing the patient's eligibility for the trial:\n\n1. High risk lymph node positive breast cancer defined as 5 or more involved axillary lymph nodes.\n   - The patient's note confirms 5 positive lymph nodes.\n\n2. Must have undergone surgical local therapy (modified radical mastectomy or breast conserving surgery).\n   - The patient is a candidate for tumor resection, but it's not clear if surgery has already been performed.\n\n3. Negative tumor margins for invasive cancer.\n   - There's no information about the tumor margins post-surgery.\n\n4. No evidence of distant metastasis.\n   - The patient's note indicates the presence of metastatic lesions on the CXR.\n\n5. Normal cardiac ejection fraction.\n   - There's no information about the patient's cardiac ejection fraction.\n\n6. Adequate organ function defined as: ANC > 1200/mm3, Platelet count > 100,000/mm, Serum creatinine < 2.0 mg/dl, Serum bilirubin < 1.5 x ULN.\n   - There's no information provided about the patient's organ function.\n\n7. Performance status 0-1.\n   - There's no information provided on the patient's performance status.\n\n8. Age 18 years or older.\n   - The patient is 45 years old.\n\n9. No prior chemotherapy, hormonal therapy or radiation therapy for treatment of the primary breast cancer.\n   - There's no evidence that the patient has started any of these treatments.\n\n10. Bilateral synchronous breast cancer is allowed if other criteria are met.\n    - There's no indication of bilateral synchronous breast cancer.\n\n11. Patients may be ER/PR+ and receive treatment with hormonal therapy (tamoxifen or aromatase inhibitors).\n    - The patient is ER/PR negative.\n\n12. Use of effective means of contraception (men and women) in subjects of child-bearing potential.\n    - The patient is postmenopausal and not sexually active.\n\n13. Signed informed consent.\n    - There's no information about whether informed consent has been provided, but it is typically obtained during the trial recruitment process.\n\nBased on the patient note and the inclusion criteria:\n- The patient does meet the age criteria.\n- The patient does have high risk lymph node positive breast cancer with 5 involved axillary lymph nodes.\n- The patient has evidence of distant metastasis, which is an exclusion criterion as per the trial's requirement for no evidence of distant metastasis.\n- There is insufficient information on some criteria (e.g., surgery completion and status, cardiac function, organ function levels, performance status, informed consent).\n\nGiven the presence of distant metastasis, the patient would be excluded from the trial. Therefore:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "64": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Spousal Relationships and Pain in Metastatic Breast Cancer,\" we need to evaluate the provided patient note against the trial's inclusion criteria.\n\nThe inclusion criteria for the trial are as follows:\n1. Being a female patient diagnosed with metastatic breast cancer.\n2. Initiating treatment for metastatic breast cancer.\n3. Having an ECOG Performance Status Score of 2 or less.\n4. For Spouses: Being the male spouse or significant other of a female patient diagnosed with metastatic breast cancer.\n5. For Spouses: Having the patient's consent to be contacted.\n6. For Patients and Spouses: Having the ability to read and speak English well enough to understand the consent form and complete the questionnaires.\n7. For Patients and Spouses: Being able to provide informed consent.\n\nNow, let's assess the patient based on the information provided in the patient note:\n1. The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which meets the first criterion.\n2. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which suggests that she is initiating treatment for metastatic breast cancer, thus meeting the second criterion.\n3. The ECOG Performance Status Score is not provided in the patient note, so we cannot confirm whether the patient meets the third criterion.\n4. There is no information given about a spouse or significant other, so we cannot assess the fourth and fifth criteria.\n5. The patient's ability to read and speak English is not mentioned, so we cannot confirm the sixth criterion.\n6. The patient's ability to provide informed consent is implied but not explicitly stated, meaning the seventh criterion is not fully confirmed.\n\nGiven that the patient note lacks specific information on the ECOG Performance Status Score, spouse or significant other's information, and the patient's ability to read and speak English, we cannot confirm the patient's eligibility for the trial.\n\nTherefore, based on the available information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "65": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to match the patient's characteristics and condition with the inclusion criteria listed for the trial.\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Confirmed breast cancer diagnosis (cytologically confirmed, invasive ductal breast carcinoma)\n- HER2-positive, ER/PR negative\n- Metastatic lesions present (Stage IV breast cancer)\n- Candidate for tumor resection prior to chemotherapy\n- No mention of prior endocrine or chemotherapy treatment for breast cancer\n\nClinical trial inclusion criteria:\n- Histologic, pathologic, or cytologic diagnosis of cancer of the female breast (met)\n- Stage IV breast cancer or locally advanced (stage III) breast cancer not amenable to curative therapy (met)\n- Tumors must be hormone receptor-positive (ER and/or PgR positive) (not met, the patient's tumor is ER/PR negative)\n- HER2 status can be any (met)\n- Must have at least one measurable lesion as per the specified criteria (not enough information to determine)\n- Must have had one or two prior endocrine treatments for breast cancer (not met, no prior treatment mentioned)\n- Tumors potentially sensitive to endocrine therapy, defined as >= 3 months of prior endocrine therapy without disease progression (not met, no prior treatment mentioned)\n- Must have had prior treatment with a third-generation aromatase inhibitor (not met, no prior treatment mentioned)\n- May have received up to one prior chemotherapy regimen for stage IV breast cancer (not met, no prior treatment mentioned)\n- No prior fulvestrant therapy (met, no prior treatment mentioned)\n- Must be postmenopausal (met)\n- ECOG performance status 0-2 (not enough information to determine)\n- Must not have a visceral crisis, bleeding disorders, or need for therapeutic systemic anticoagulation (not enough information to determine)\n- Adequate organ function as specified by the listed laboratory values (not enough information to determine)\n\nGiven the information available in the patient note, the patient does not meet the inclusion criteria regarding hormone receptor status and prior treatments. The patient's tumor is HER2-positive and ER/PR negative, which does not align with the trial's requirement for hormone receptor-positive tumors. Also, there is no mention of prior endocrine or chemotherapy treatment, which is a requirement for the trial.\n\nTherefore, based on the available information, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "66": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer that is HER2-positive and ER/PR negative. The tumor is invasive, located in the left upper outer quadrant, and there is evidence of metastasis as indicated by the presence of 5 positive lymph nodes and metastatic lesions on the CXR. The patient is also a candidate for tumor resection, which she agrees to undergo prior to chemotherapy.\n\nNow, looking at the clinical trial's inclusion criteria, the trial is looking for patients with:\n\n- Breast cancer with evidence of unresectable locally recurrent, or metastatic disease\n- Her-2 negative tumors\n\nWhile the patient does have breast cancer with metastatic disease, which fits the first criterion, the tumor is HER2-positive. The inclusion criteria specifically require Her-2 negative tumors. Therefore, this patient does not meet the inclusion criteria because the tumor's HER2 status is positive, which is a mismatch with the trial's requirement for HER2-negative tumors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "67": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. According to the clinical trial's inclusion criteria, the trial is looking for participants with:\n\n- Metastatic or locally advanced breast cancer not amenable to curative surgery\n- Life expectancy of greater than 12 months\n- English speaking\n- Pre- and postmenopausal\n- Performance status 0-1\n\nThe patient's note indicates that she has metastatic breast cancer, as evidenced by metastatic lesions noted in the CXR (chest X-ray). Although the patient's life expectancy is not explicitly mentioned, the fact that she is a candidate for tumor resection prior to chemotherapy suggests that her medical team believes she has a significant life expectancy, likely greater than 12 months. The patient's language abilities are not mentioned, but for the purpose of this eligibility check, we will assume she speaks English unless otherwise stated. The patient is postmenopausal, which fits the criteria. The performance status is not mentioned, but the patient is a candidate for surgery, which may suggest a good performance status (typically, a performance status of 0-1 indicates that the patient is fully active or restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).\n\nGiven the information available, the patient appears to meet the inclusion criteria for the clinical trial. However, without explicit details on her performance status and confirmation of her English-speaking ability, we cannot be certain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "68": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients,\" we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nHere are the relevant points from the patient's note:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is a 3 cm invasive ductal carcinoma, HER2-positive, and ER/PR negative.\n- Five positive lymph nodes were found via axillary sampling.\n- Metastatic lesions were observed on CXR.\n- The patient is scheduled for tumor resection.\n\nNow, let's compare these to the inclusion criteria of the trial:\n\nInclusion Criteria Checklist:\n- Histologically or cytologically confirmed breast adenocarcinoma. [\u2713]\n- Within 20-45 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed. [?]\n- Absence of lymph node involvement after eclosion and hormone (E&H) staining and light microscopy evaluation. [X] (The patient has positive lymph nodes.)\n- Premenopausal or postmenopausal women with at least one of the following tumor characteristics is required to characterize the tumor as high risk:\n  - Estrogen receptor (ER) (-) and progesterone receptor (PR)(-); [\u2713]\n  - Ki-67 + > 30%; Grade III; HER2 (3+) (after an amendment on 15.05.2008 women with HER2 (3+) were not included); Perineural infiltration or presence of tumor emboli in blood or lymph vessels. [?] (HER2-positive status is mentioned, but inclusion after amendment is unclear, as well as other factors.)\n- Postmenopausal women with tumors 1-2 cm are eligible if the tumor has at least 2 of the above-mentioned high-risk criteria. [X] (The tumor is larger than 2 cm.)\n- Premenopausal and postmenopausal women with tumors measuring > 2 cm are eligible irrespectively of the expression of the above adverse prognostic tumor criteria. [\u2713]\n- Absence of any clinical or radiological evidence of local or metastatic disease. [X] (The patient has metastatic lesions.)\n- Age > 18 years. [\u2713]\n- Performance status (WHO) < 3. [?]\n- Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count > 100000/mm^3, hemoglobin > 9 gr/mm^3). [?]\n- Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times upper limit of normal) and renal function (creatinine < 2 mg/dl). [?]\n- Adequate cardiac function (LVEF > 50%). [?]\n- Negative pregnancy test. [N/A, postmenopausal]\n- Informed consent. [?]\n\nThe patient is excluded from the trial due to the presence of lymph node involvement and evidence of metastatic disease, both of which are contrary to the trial's inclusion criteria which require an absence of lymph node involvement and no clinical or radiological evidence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "69": {
        "output": "Upon reviewing the patient's note and the clinical trial's inclusion criteria, we can assess the patient's eligibility as follows:\n\n1. Women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma: The patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal carcinoma.\n\n2. Within 60 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, it is not stated whether the surgery has already been performed or that 10 lymph nodes have been removed.\n\n3. Tumor involvement of at least one axillary lymph node: The patient has 5 positive lymph nodes.\n\n4. Absence of any clinical or radiological evidence of local or metastatic disease: The patient's CXR was remarkable for metastatic lesions, which indicates the presence of metastatic disease.\n\n5. Premenopausal or postmenopausal women aged 18-75 years old: The patient is a 45-year-old postmenopausal woman.\n\n6. Adequate bone marrow function: The patient's bone marrow function is not mentioned.\n\n7. Adequate liver and renal function: The patient's liver and renal function are not mentioned.\n\n8. Adequate cardiac function (LVEF>50%): The patient's cardiac function is not mentioned.\n\n9. Written informed consent: The patient has agreed to tumor resection, which suggests a willingness to participate, but this does not confirm that informed consent for the trial has been provided.\n\nThe patient does not meet the inclusion criteria due to the presence of metastatic disease, which is explicitly excluded by the trial's requirement for an \"Absence of any clinical or radiological evidence of local or metastatic disease.\" Even though there is no specific exclusion criteria provided, the inclusion criteria itself serves to exclude this patient.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "70": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- Age: 45 years old\n- Gender: Female\n- Condition: Invasive ductal breast carcinoma, HER2-positive, ER/PR-negative\n- Other: Postmenopausal, candidate for tumor resection, agrees to chemotherapy prior to surgery\n\nClinical trial inclusion criteria:\n- Signed and dated informed consent form\n- Women \u2265 18 years, negative pregnancy test at screening, life expectancy of at least 6 months\n- Locally advanced (stage IIIb) or metastatic (stage IV) and not curable adenocarcinoma of the breast\n- Measurable disease, defined as at least one lesion that is measurable in one dimension (RECIST)\n- HER-2/neu expression 1+ or 2+ / FISH negative\n- Estrogen Receptors (ERs) and/or Progesterone Receptors (PRs) positive\n- Prior adequate endocrine therapy for advanced or metastatic disease\n- Disease progression during or after endocrine therapy\n- No prior treatment with mouse or rat antibodies\n- ECOG performance score of \u2264 1\n- Adequate hematological, liver and kidney function\n\nComparison:\n- The patient is a 45-year-old woman, which meets the age and gender criteria.\n- The patient has metastatic breast cancer, meeting the condition of locally advanced or metastatic adenocarcinoma of the breast.\n- The patient's tumor is HER2-positive, which aligns with the HER-2/neu expression requirement.\n- The patient has measurable disease as the tumor is 3 cm, which fulfills the criteria of having at least one measurable lesion.\n- However, the patient's tumor is ER/PR-negative, which does not meet the requirement of ERs and/or PRs being positive.\n- There is no mention of prior endocrine therapy, disease progression during or after endocrine therapy, or prior treatment with mouse or rat antibodies. Additionally, the patient's ECOG performance score and organ function status are not specified.\n\nGiven the information, the patient does not meet the criteria of having ERs and/or PRs positive. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "71": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"TAC Versus TC for Adjuvant Breast Cancer,\" we need to compare the patient's characteristics and medical history with the inclusion criteria listed for the trial.\n\nLet's evaluate the patient based on the inclusion criteria:\n\n1. Age >18 to <70 years old: The patient is 45 years old, which meets the age criterion.\n2. Has known ER and PR status: The patient's tumor is ER/PR negative.\n3. Has HER2 nonamplified disease, confirmed by FISH: The patient's tumor is HER2 positive, which does not meet this criterion.\n4. Has known menopausal status: The patient is postmenopausal.\n5. Has operable, histologically confirmed, Stage I, IIA, IIB, or IIIA, IIIB, or IIIC invasive carcinoma of the breast: The patient has invasive ductal breast carcinoma, but the stage is not specified.\n6. Meets 1 of the 3 following criteria: The patient's tumor is ER and PR negative, which meets one of the criteria (T1N0M0 if ER and PR negative).\n7. Has complete surgical resection of the primary breast tumor: The patient is a candidate for tumor resection.\n8. Has had no prior chemotherapy: The patient has not undergone chemotherapy yet.\n9. Has an ECOG Performance Status (PS) 0-1: Not specified in the patient's note.\n10. Has laboratory values within the specified ranges: Not specified in the patient's note.\n11. Has normal cardiac function: Not specified in the patient's note.\n12. Has no evidence of metastatic disease outside of breast by physical examination and chest x-ray: The patient has metastatic lesions noted on CXR.\n13. Has had baseline bilateral mammography: Not specified in the patient's note.\n14. It has been <84 days since the date of definitive surgery: The patient has not had surgery yet.\n15. Has a negative serum pregnancy test within 7 calendar days prior to registration: Not applicable as the patient is postmenopausal.\n16. If fertile, has agreed to use an acceptable method of birth control: Not applicable as the patient is postmenopausal.\n17. Has adequate tumor specimen available for FISH analysis of TOP2A status: Not specified in the patient's note.\n18. Has signed a Patient Informed Consent Form and a Patient Authorization Form: Presumed to be obtainable if other criteria are met.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the following reasons:\n- The patient's tumor is HER2 positive, while the trial requires HER2 nonamplified disease.\n- The patient has evidence of metastatic disease, which is an exclusion criterion for the trial.\n\nGiven the mismatch with the HER2 status and the presence of metastatic disease, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "72": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer,\" we must compare the patient's characteristics and medical condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- The patient is a 45-year-old postmenopausal woman.\n- Cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR showed metastatic lesions.\n- The patient is a candidate for tumor resection prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- Females age 18 years or older.\n- Histologically confirmed infiltrating (invasive) breast cancer by core needle biopsy, with no evidence of metastatic disease except to the ipsilateral axillary lymph nodes.\n- Clinical stage IIB - IIIC (T2-4, N0 or N1, M0 or - any T, N1-3, M0) breast cancer.\n- Clinically palpable tumor greater than or equal to 2 cm (T2-4) or with pathologically proven axillary nodal involvement (N1-3).\n- Primary tumor may be estrogen or progesterone receptor negative or positive, and HER-2/neu negative as determined by FISH or 0-2+ staining by IHC.\n- Normal cardiac ejection fraction (EF \u2265 50%).\n- No prior history of myocardial infarction, congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias.\n- ECOG Performance Status of 0-1.\n- Ability to self administer daily subcutaneous injections.\n- Life expectancy greater than 6 months.\n\nComparison:\n- The patient meets the age criterion (45 years old).\n- The patient has histologically confirmed invasive breast cancer, satisfying this criterion.\n- The patient has a tumor greater than 2 cm and axillary nodal involvement, meeting this criterion.\n- The patient's tumor is HER2-positive, which does not meet the inclusion criterion of being HER-2/neu negative as determined by FISH or 0-2+ staining by IHC.\n- The presence of metastatic lesions on CXR indicates that the patient has evidence of metastatic disease beyond the ipsilateral axillary lymph nodes, which does not meet the inclusion criterion of having no evidence of metastatic disease except to the ipsilateral axillary lymph nodes.\n\nBased on the provided information, the patient does not meet all of the inclusion criteria for the clinical trial due to having a HER2-positive tumor and the presence of metastatic disease beyond the ipsilateral axillary lymph nodes. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "73": {
        "output": "The patient in the note is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, specifically invasive ductal breast carcinoma that is HER2-positive and ER/PR negative with axillary lymph node involvement and metastatic lesions. She is currently being considered for tumor resection prior to chemotherapy.\n\nThe clinical trial in question is focused on patients with stage IA non-small cell lung cancer (NSCLC) and compares the effectiveness of different types of surgery (wedge resection or segmentectomy versus lobectomy). The inclusion criteria for this trial specify that the patient must have a peripheral lung nodule presumed to be lung cancer, no prior malignancy within 3 years (with certain exceptions), no prior chemotherapy or radiation for this malignancy, no evidence of advanced or metastatic disease, an ECOG performance status of 0-2, and be at least 18 years of age.\n\nGiven that the patient has breast cancer with metastatic involvement, she does not meet the inclusion criteria for a trial focused on stage IA non-small cell lung cancer without evidence of metastatic or locally advanced disease. Additionally, there is no mention of lung cancer in the patient's diagnosis. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "74": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's information to the inclusion criteria listed for the trial. Here are the relevant points from the patient note and the inclusion criteria:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions present (CXR)\n- Candidate for tumor resection\n- No mention of ECOG performance status or left ventricular ejection fraction (LVEF)\n\nClinical Trial Inclusion Criteria:\n- Histologically or cytologically confirmed invasive breast carcinoma\n- Early stage breast cancer - stage I (tumor size greater than 1 cm), II and IIA\n- 3+ HER2 overexpression by IHC or 2+ HER2 overexpression and FISH positivity\n- Measurable disease as defined by the criteria mentioned\n- ECOG performance status 0 to 2 within 14 days of study entry\n- Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography\n- Must be 18 years of age or older\n- Women of childbearing potential must use appropriate contraceptive methods. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential\n\nComparison:\n\n- The patient has confirmed invasive breast carcinoma, fulfilling the first criterion.\n- The patient has early-stage breast cancer, and the tumor size is greater than 1 cm, fulfilling the second criterion.\n- The patient's tumor is HER2-positive, which meets the third criterion.\n- There is measurable disease as per the core biopsy and metastatic lesions, which seems to fulfill the fourth criterion.\n- The patient is over 18 years old, fulfilling the age requirement.\n- The patient is postmenopausal, which addresses the requirement for contraception.\n\nThe patient note does not provide information on the patient's ECOG performance status or LVEF. These are required for the clinical trial inclusion and are not mentioned in the patient note.\n\nBased on the information provided, the patient seems to meet most of the inclusion criteria. However, due to the lack of information on the ECOG performance status and LVEF, we cannot definitively determine eligibility without these key pieces of data.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "75": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\n- The patient is a 45-year-old postmenopausal woman, which meets the trial's criterion of being female and 18 years of age or older.\n- The patient has a clinical tumor size of 3 cm, which could be classified as T1 or T2, thus meeting the criterion for tumor size (T1, T2, or T3).\n- The patient has a histopathologic tissue diagnosis of breast cancer by a core-type of breast biopsy, which meets the trial's requirement for a core biopsy.\n- The patient has biopsy-proven involvement of the axillary lymph nodes, based on the note that axillary sampling revealed 5 positive lymph nodes. This fits the requirement for biopsy-proven axillary lymph node involvement.\n- The patient note does not specify that the patient has undergone preoperative neoadjuvant systemic chemotherapy. Instead, it states that she is a candidate for tumor resection and agrees to proceed with it prior to chemotherapy. This suggests that neoadjuvant chemotherapy has not yet been administered, which does not meet the requirement of the trial that patients must have undergone preoperative neoadjuvant systemic chemotherapy.\n\nGiven this information, the patient does not meet all the inclusion criteria due to not having undergone neoadjuvant systemic chemotherapy prior to the potential resection. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "76": {
        "output": "",
        "label": 1
    },
    "77": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The clinical trial in question is focused on patients with epilepsy, specifically those with medically-refractory epilepsy, who have had treatment failure of at least 2 anti-epilepsy drugs and have a certain frequency of seizures.\n\nBased on the provided patient note, this patient does not meet the inclusion criteria for the epilepsy clinical trial as she has breast cancer and there is no mention of her having epilepsy or being treated for seizures. Therefore, she is not relevant for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "78": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer,\" we need to compare the inclusion criteria with the patient's medical details.\n\nHere are the key points from the patient's medical history:\n- The patient is a 45-year-old postmenopausal woman with breast cancer.\n- Histologically confirmed invasive ductal carcinoma.\n- A tumor size of 3 cm (within the specified size of \u2264 3 cm).\n- Axillary sampling revealed 5 positive lymph nodes, which means the patient has more than the maximum allowed 3 positive lymph nodes according to the trial criteria.\n- The patient has distant metastatic lesions, as indicated by the CXR finding.\n\nAnd the relevant inclusion criteria for the trial:\n- Female patient (met).\n- Histologically confirmed breast cancer, with specific allowed subtypes including invasive ductal carcinoma (met).\n- Stage I or II disease with the lesion \u2264 3 cm (met in terms of lesion size, but not clearly stated stage).\n- No more than 3 positive lymph nodes (not met - the patient has 5 positive lymph nodes).\n- No distant metastatic disease (not met - the patient has metastatic lesions).\n\nBased on the information provided, the patient does not meet the eligibility criteria for the clinical trial due to having more than 3 positive lymph nodes and the presence of distant metastatic disease. Therefore, the patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "79": {
        "output": "Let's evaluate the eligibility of the patient for the clinical trial titled \"Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer\" based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection, planning to undergo surgery prior to chemotherapy\n- No mention of prior treatment history\n- No mention of hematopoietic, renal, hepatic, cardiac, or mental function\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed and newly diagnosed breast cancer: node-positive stage IIA and any stage IIB, III\n- No prior hormonal, chemotherapy, or radiotherapy\n- No breast operation other than biopsy for diagnosis\n- Age: 18 years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1)\n- Adequate hematopoietic function\n- Adequate renal function\n- Adequate hepatic function\n- Adequate cardiac function\n- Adequate mental function to understand and sign consent\n\nComparison:\n- The patient has histologically confirmed breast cancer and is postmenopausal, which aligns with the inclusion criteria.\n- The patient has positive lymph nodes and metastatic lesions, which would likely place her at a clinical stage consistent with the trial's inclusion criteria (IIA, IIB, III).\n- There is no mention of any prior hormonal, chemotherapy, or radiotherapy, so we can assume the patient has not received these treatments yet.\n- The patient is planning to have a tumor resection, which is not allowed by the trial if it happens before enrollment; however, as it is planned and not yet conducted, it does not currently exclude her.\n- The age of the patient is within the required range.\n- There are no details provided regarding the patient's performance status or her hematopoietic, renal, hepatic, cardiac, or mental function. \n\nBased on the information provided, the patient appears to meet most of the inclusion criteria. However, since there is no information on her performance status (ECOG 0-1), or her hematopoietic, renal, hepatic, cardiac, and mental function, we cannot definitively determine her eligibility. Therefore, the patient falls into the category of \"Not relevant\" due to insufficient information to confirm eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "80": {
        "output": "To assess the eligibility of the 45-year-old postmenopausal woman with breast cancer for the clinical trial titled \"Effect of SBG in Patients With Breast Cancer,\" we need to compare her patient note to the inclusion criteria of the trial.\n\nLet\u2019s evaluate each criterion one by one:\n\n1. Women with histologically/cytologically confirmed locally advanced or metastatic breast cancer.\n   - The patient note confirms that she has cytologically confirmed breast cancer with metastatic lesions seen on CXR.\n\n2. Primary tumor or metastases are HER2-ICH3+ or FISH+\n   - The patient note confirms that the tumor is HER2-positive.\n\n3. Measurable or non-measurable disease.\n   - The patient has a measurable 3 cm invasive ductal breast carcinoma.\n\n4. The patients must not have received treatment with the combination trastuzumab and vinorelbine previously.\n   - The patient note does not mention any previous treatment with trastuzumab and vinorelbine.\n\n5. Expected lifetime of more than 12 weeks.\n   - The patient note does not provide any details on the expected lifetime, but she is a candidate for tumor resection, which suggests that her expected lifetime might be more than 12 weeks.\n\n6. Age \u2265 18 years.\n   - The patient is 45 years old.\n\n7. Performance status \u2264 2 according to World Health Organization (WHO) scale.\n   - The patient note does not specify her performance status. However, because she is a candidate for tumor resection and agrees to proceed with it prior to chemotherapy, this may indicate a performance status of \u2264 2, but this is an assumption as the performance status is not explicitly stated.\n\n8. The patient must be able to comply with the protocol.\n   - The patient note does not provide information about her ability to comply with the protocol, but her agreement to tumor resection suggests she is willing to be treated, which may indicate compliance.\n\n9. Verbal and written informed consent.\n   - The patient note does not mention whether she has given informed consent, but since she is a candidate for tumor resection, we can assume she is capable of giving consent.\n\nBased on the information available in the patient note, the patient appears to meet all the inclusion criteria for the clinical trial. The only information not explicitly provided is her performance status and her ability to comply with the protocol. However, since she is a candidate for surgery, it is likely that her performance status is adequate and that she can comply with the trial requirements. Therefore, we can consider her eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "81": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's compare the patient's characteristics and condition with the trial's requirements:\n\nPatient Characteristics:\n- Age: 45 years old (meets the criterion of age \u2265 18 years)\n- Diagnosis: Cytologically confirmed breast cancer\n- Tumor Details: Invasive ductal breast carcinoma, 3 cm, left upper outer quadrant, HER2-positive, ER/PR-negative\n- Treatment Plan: Candidate for tumor resection, to be followed by chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Women with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 negative invasive breast cancer confirmed on core biopsy. (HER2 0 or 1+ by IHC acceptable)\n- Primary tumor size 2 cm or greater.\n- Assessment of pre-treatment axillary lymph nodal status.\n- Absolute neutrophil count > 1500 mm3 and platelet count > 100,000 mm3 (patient's bloodwork not provided in the note, so this remains unknown).\n- Normal myocardial left ventricular function (no information provided about the patient's cardiac function).\n- Serum creatinine < 2.0 mg/dl (no information provided about the patient's renal function).\n- Total bilirubin and AST < 3X upper limits normal (no information provided about the patient's liver function).\n\nEligibility Assessment:\n- The patient's tumor is HER2-positive, which does not meet the trial's requirement for HER2-negative status.\n- The patient does meet the age criterion.\n- The primary tumor size meets the trial's requirement (3 cm).\n- The patient has had axillary sampling with positive lymph nodes, which provides information on nodal status, although the specific method preferred by the trial is not mentioned.\n\nBased on the information provided, the patient does not meet the criteria for HER2 status, as the trial specifically requires HER2-negative patients and the patient's tumor is HER2-positive. Therefore, despite meeting other criteria, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "82": {
        "output": "To determine the patient's eligibility for the clinical trial \"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE),\" let's compare the patient's information with the inclusion criteria of the trial:\n\nPatient information:\n- 45-year-old postmenopausal woman\n- Histologically confirmed breast cancer (invasive ductal breast carcinoma)\n- Tumor size: 3 cm\n- HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR revealed metastatic lesions\n- Candidate for tumor resection, agreeing to undergo surgery prior to chemotherapy\n- No mention of systemic metastasis exclusion by sonogram of the upper abdomen and skeletal scintiscan\n- Age fits the criteria (\u226518 years and \u226465 years)\n- No mention of ECOG/WHO performance status\n- No information about organ function or specific lab values\n- No information provided regarding heart echo results\n- No mention of hepatitis status\n- Willingness to participate (implied by agreement to tumor resection as part of treatment)\n\nInclusion criteria for the trial:\n- Histologically confirmed breast cancer with at least three fast biopsies\n- Primary tumor \u22652 cm according to clinical measurement or manifestation of an inflammatory breast cancer\n- No systemic metastasis, exclusion by chest x-ray, sonogram of the upper abdomen, and skeletal scintiscan\n- Age \u226518 years and \u226465 years\n- ECOG < 2/WHO 0-1\n- Adequate organ function (specific lab values provided)\n- Unremarkable heart echo\n- No florid hepatitis\n- Written consent to participate in the treatment optimization protocol\n\nBased on the given information, the patient has confirmed breast cancer with a tumor size that fits the criteria, and her age is within the required range. However, the patient's eligibility cannot be fully determined due to the following gaps in the information provided:\n- The patient has CXR showing metastatic lesions, which may indicate systemic metastasis. This would exclude her from the trial as per the \"no systemic metastasis\" criterion.\n- The patient's ECOG/WHO performance status is not mentioned.\n- There is no information about the patient's specific organ function through lab values, heart echo results, or hepatitis status.\n- While the patient's agreement to tumor resection implies willingness to participate in treatment, there is no explicit mention of written consent for the trial itself.\n\nGiven the presence of metastatic lesions, it is likely that the patient does not meet the \"no systemic metastasis\" criterion, which would exclude her from the trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "83": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer,\" we need to evaluate the patient's characteristics and medical history against the inclusion criteria of the trial:\n\nInclusion Criteria Assessment:\n1. Postmenopausal women: The patient is described as postmenopausal.\n2. Histologically or cytologically confirmed breast cancer: The patient has cytologically confirmed breast cancer.\n3. Metastatic breast cancer (Stage IV according to UICC criteria, Version 6): The patient has metastatic lesions noted on CXR.\n4. Progesterone receptor-positive tumors: The patient's tumor is HER2-positive and ER/PR negative, which means it does not have progesterone receptors.\n5. Candidates for endocrine therapy: The patient is a candidate for tumor resection before chemotherapy, but the eligibility requirement is for patients who are candidates for endocrine therapy.\n6. Disease progression after first-line endocrine therapy for advanced breast cancer: There is no information provided about the patient having previously received endocrine therapy or disease progression after such therapy.\n7. At least one measurable or non-measurable tumor lesion: The patient has a 3 cm invasive ductal breast carcinoma, which is a measurable lesion.\n8. WHO Performance status 1: There is no information provided on the patient's performance status.\n9. Adequate function of major organs and systems: There is no information provided on the patient's organ function.\n10. No other uncontrolled concurrent illness: There is no information provided about any concurrent illness.\n11. Adequate recovery from previous surgery, radiation, and chemotherapy: The patient agrees to undergo tumor resection, but there is no information about recovery as no treatment has been administered yet.\n12. Written informed consent: Not applicable for this assessment.\n\nThe patient does not meet eligibility on the basis of having a progesterone receptor-positive tumor, as her tumor is PR negative. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "84": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can determine the patient's eligibility as follows:\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The cancer is invasive ductal carcinoma, HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes, indicating that the lymph nodes are not negative.\n- There are metastatic lesions present, as indicated by the CXR.\n- The patient is a candidate for tumor resection.\n\nClinical Trial Inclusion Criteria Analysis:\n- Female sex (Patient meets this criterion)\n- Age greater than or equal to 40 years (Patient meets this criterion)\n- Localized ductal carcinoma in situ (Patient does not meet this criterion as her cancer is invasive)\n- Clinically and/or histologically negative axillary lymph nodes (Patient does not meet this criterion as she has 5 positive lymph nodes)\n- No imaging or clinical findings suggestive of invasive carcinoma (Patient does not meet this criterion as she has invasive carcinoma and metastatic lesions)\n\nBased on the patient's diagnosis of invasive ductal carcinoma with positive lymph nodes and metastatic lesions, she does not meet the inclusion criteria for the clinical trial which specifically requires patients with localized ductal carcinoma in situ, negative axillary lymph nodes, and no findings of invasive carcinoma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "85": {
        "output": "",
        "label": 0
    },
    "86": {
        "output": "To determine the trial-level eligibility for the patient described in the patient note, we have to compare the patient's information to the inclusion criteria of the clinical trial for preoperative cisplatin and bevacizumab in ER-, PR-, HER2-negative breast cancer.\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR was remarkable for metastatic lesions (presence of metastases, which suggests stage M1)\n- Candidate for tumor resection, agrees to surgery prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- All tumors must be ER-, PR- and HER2-negative\n- Clinical stage T2 or T3, N0-3, M0 (the trial excludes subjects with inflammatory breast cancer or metastatic disease, which would be stage M1)\n- 18 years of age or older\n- Performance status (PS) of 0 or 1\n- Use of an effective means of contraception in subjects of child-bearing potential\n- Normal organ function as described in the protocol\n\nComparison:\n- The patient is 45 years old, which meets the age criterion.\n- The patient has a performance status that is not explicitly stated but is likely to be 0 or 1, as she is a candidate for surgery.\n- The use of contraception is not relevant as the patient is postmenopausal.\n- The patient has ER/PR-negative breast cancer, which meets part of the trial's criteria for tumor characteristics. However, the patient's tumor is HER2-positive, which does not meet the trial's requirement for HER2-negative status.\n- The patient has metastatic lesions (M1), which do not meet the trial's requirement for M0 (no metastasis).\n\nBased on the comparison, the patient is not eligible for the trial because her tumor is HER2-positive, and she has metastatic disease, which are both exclusionary according to the trial's criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "87": {
        "output": "To determine the patient's eligibility for the clinical trial, I will compare the patient's information provided in the note with the inclusion criteria specified for the clinical trial:\n\nPatient Information:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Core biopsy: 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: metastatic lesions\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Unifocal histologically proven breast cancer, with or without calcifications in mammogram\n- DCIS (Ductal carcinoma in situ) (Tis, Stage 0)\n- Non-lobular infiltrating carcinoma, maximum of 2 cm in diameter (T1, Stage I)\n- Patient was operated on and the tumor was excised with lumpectomy\n- Tumor with negative margins >3 mm\n- For invasive carcinoma, axillary lymph nodes are negative\n- Patient is over 40 years old with life expectancy of at least 5 years\n- Karnofsky status must be at least 70\n- Pre- and post-menopausal women are eligible\n- Informed consent must be provided\n\nComparison:\n- The patient's age fits the trial criteria (over 40 years old).\n- The patient is postmenopausal, which is acceptable according to the trial criteria.\n- The patient has a histologically proven breast cancer, which fits the trial criteria.\n- The patient has not yet undergone tumor excision, which is required before participation in the trial.\n- The patient's tumor is larger than 2 cm in diameter, which exceeds the trial's size limit.\n- The patient has positive axillary lymph nodes, which is contrary to the trial's requirement of negative axillary lymph nodes.\n- The patient has metastatic lesions, and the trial specifies early-stage, lymph node negative breast cancer.\n\nBased on the comparison, the patient does not meet several key inclusion criteria for the clinical trial. Specifically, the tumor size and the status of axillary lymph nodes, as well as the early-stage breast cancer requirement, exclude the patient from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "88": {
        "output": "Upon reviewing the patient's information and the clinical trial's inclusion criteria, let's analyze the compatibility step by step:\n\n1. Age: The patient is 45 years old, which meets the age inclusion criteria of \u2265 18 years.\n2. Disease: The patient has invasive ductal breast carcinoma, which is one of the eligible histologies mentioned in the trial inclusion criteria.\n3. AJCC Stage: The patient has metastatic lesions as per the CXR report, indicating that the cancer has spread beyond the local and regional lymph nodes. This suggests a stage beyond II, making the patient ineligible based on the AJCC stage 0, I, or II criteria.\n4. Treatment: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, the inclusion criteria specify that the patient must be treated with tylectomy. There is no information about whether the patient has undergone a tylectomy or is planning to undergo one.\n5. Axillary Nodes: The patient has 5 positive lymph nodes, which contradicts the trial's inclusion criteria of having no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.\n6. Margins: There is no information provided about the margins of the patient's tumor resection.\n7. Chemotherapy or hormonal therapy: The patient is a candidate for chemotherapy after tumor resection, which is allowed in the trial criteria as long as it is planned for \u2265 2 weeks after removal of the brachytherapy catheters.\n8. Pregnancy: There is no mention of a pregnancy test, but the patient is postmenopausal, which implies a negative pregnancy status.\n\nBased on the available information, the patient does not meet the AJCC stage criteria and has positive axillary lymph nodes, which is not in line with the trial's inclusion criteria. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "89": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer,\" we need to compare the patient's characteristics and disease status with the inclusion criteria of the trial.\n\nHere are the relevant points from the patient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions noted on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nAnd here are the key inclusion criteria from the clinical trial:\n- Female\n- Stage I-II invasive or intraductal breast cancer\n- Unifocal tumor \u2264 3.0 cm in size\n- Fewer than 4 positive nodes on adequate axillary lymph node dissection\n\nNow, let's compare the patient's data with the clinical trial's inclusion criteria:\n\n- The patient is a 45-year-old postmenopausal woman, which fits the gender requirement.\n- The tumor is unifocal and 3 cm in size, which is within the limit specified.\n- However, the patient has 5 positive lymph nodes, which exceeds the maximum of 3 positive nodes allowed by the trial's criteria.\n\nSince the patient does not meet the criteria regarding the number of positive lymph nodes, she is not eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "90": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Histologically confirmed invasive ductal breast carcinoma\n- 3 cm tumor size\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Evidence of metastatic lesions on CXR\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed primary invasive breast carcinoma\n- Stage I-IIA disease (T1, N0, M0 or T2, N0, M0)\n- Single, discrete, and well-defined primary tumor \u2264 5 cm in diameter\n- Pathologically negative surgical margins\n- No multicentric disease and/or diffuse malignant appearing microcalcifications\n- No axillary lymph node involvement\n- No evidence of metastatic breast cancer\n- ECOG performance status 0-2\n- Menopausal status not specified\n- No pre-existing collagen vascular disease except rheumatoid arthritis\n- Not pregnant or nursing\n- No prior irradiation to the area of planned radiation field\n- No prior placement of breast prosthesis in the treated breast\n- Concurrent hormonal therapy with external-beam irradiation allowed\n\nAssessment:\n- The patient has breast carcinoma, which matches the disease characteristic requirement.\n- The tumor size is within the required \u2264 5 cm in diameter.\n- The patient has axillary lymph node involvement (5 positive lymph nodes), which does not meet the 'No axillary lymph node involvement' criterion.\n- The patient has evidence of metastatic lesions, which contradicts the 'No evidence of metastatic breast cancer' criterion.\n\nThe patient does not meet the inclusion criteria due to positive lymph nodes and metastatic breast cancer presence. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "91": {
        "output": "To determine the patient's eligibility for the clinical trial, let's compare the patient's characteristics and medical history with the inclusion criteria of the trial:\n\nPatient's characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, HER2-positive, ER/PR-negative\n- Positive lymph nodes and metastatic lesions\n- Candidate for tumor resection, agreeing to undergo surgery prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Postmenopausal females\n- ER and/or PR-positive histologically confirmed adenocarcinoma of the breast\n- Measurable locally recurrent or metastatic disease\n- Must submit tissue blocks for retrospective analysis or provide slides if blocks are not available\n- Must be postmenopausal as defined by the criteria listed\n- No more than 1 prior chemotherapy regimen for metastatic disease\n- May have had 1 prior hormonal therapy for metastatic disease\n- No prior therapy with EGF receptor inhibitors\n- Previous but not concomitant therapy with trastuzumab (Herceptin) is allowed\n- ECOG performance status of 0, 1, or 2\n- Adequate organ function as defined in the criteria\n- Must be 18 years of age or older\n- No history of CNS metastases or unevaluated CNS symptoms\n- May receive concurrent radiation therapy to bone metastases if initiated prior to study entry\n- No history of invasive cancers other than exceptions listed\n- Must not have received LHRH antagonists within 3 months if < 55 years of age\n- Free from medical or psychiatric conditions that would interfere with compliance\n\nAssessment:\n- The patient has invasive ductal breast carcinoma which is HER2-positive and ER/PR-negative. The trial requires participants to have ER and/or PR-positive breast cancer. Since the patient's tumor is ER/PR-negative, she does not meet the inclusion criteria regarding the hormone receptor status of the tumor.\n- The patient has agreed to undergo tumor resection, which suggests her disease may be operable, whereas the trial requires the disease to be measurable but not operable.\n\nBased on the information provided, the patient does not meet the critical inclusion criteria of having ER and/or PR-positive breast cancer and having non-operable disease. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "92": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer,\" we need to review the patient note against the inclusion criteria listed.\n\nPatient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman, which fits within the age range of 18-75 years old specified by the trial.\n- The patient has cytologically confirmed breast cancer, specifically invasive ductal carcinoma, which is included in the histological types mentioned.\n- The tumor is HER2-positive, which meets the criteria for HER2/c-neu overexpression as required.\n- The patient has axillary lymph node involvement with 5 positive lymph nodes, meeting the requirement for tumor involvement of at least one axillary lymph node.\n- The patient is a candidate for tumor resection and agrees to undergo surgery, which suggests that the surgery could be done within 60 days after excision as required by the trial.\n- The patient is using multivitamins and iron supplements, but there's no mention of inadequate bone marrow, liver, renal, or cardiac function, so we can't determine if these criteria are met based on the provided information.\n- There is a mention of metastatic lesions on a CXR, which indicates the presence of metastatic disease. This contradicts the requirement of \"absence of any clinical or radiological evidence of local or metastatic disease.\"\n\nBased on the information provided, the patient meets several inclusion criteria, such as age, histology, HER2 status, and lymph node involvement. However, the presence of metastatic lesions excludes the patient as the trial requires the absence of any clinical or radiological evidence of metastatic disease. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "93": {
        "output": "To determine the patient's eligibility, let's go through the inclusion criteria of the clinical trial one by one and see if this patient's note provides the necessary information:\n\n1. Patients must be women with a histologically confirmed diagnosis of breast cancer that is more than 1 cm and or lymph node positive: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer and positive lymph nodes, meeting this criterion.\n\n2. Physical examination, and scans needed for tumor assessment must be performed within 90 days prior to registration: The patient note does not mention the timing of the physical examination and scans.\n\n3. Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible: The patient note does not mention either of these conditions, so we do not have information to exclude her based on this criterion.\n\n4. Serum creatinine within normal limits within 90 days prior to registration: The patient note does not provide information about serum creatinine levels.\n\n5. Bilirubin within normal limits within 90 days prior to registration: The patient note does not provide information about bilirubin levels.\n\n6. Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2 x the institutional upper limit of normal within 90 days prior to registration: The patient note does not provide information about liver enzyme levels.\n\n7. Absolute neutrophil count (ANC) of >= 1,500/microliters within 90 days prior to registration: The patient note does not provide information about ANC levels.\n\n8. Platelet count of >= 100,000/microliters within 90 days prior to registration: The patient note does not provide information about platelet count.\n\n9. Patients must have a performance status of 0-2 by Zubrod criteria: The patient note does not provide information about performance status according to Zubrod criteria.\n\n10. Pregnant or nursing women may not participate; women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnancy test required for women of childbearing potential: The patient is postmenopausal, which implies she is not of childbearing potential and not pregnant or nursing, so she meets this criterion.\n\n11. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines: The patient note does not mention consent, but this is typically obtained during the recruitment process, so we cannot determine eligibility based on this criterion at this stage.\n\nGiven that the patient meets some of the inclusion criteria but lacks sufficient information for a number of important criteria (particularly related to recent tests and specific health measurements), we cannot definitively classify her as eligible or excluded. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "94": {
        "output": "Based on the information provided, the patient has a diagnosis of invasive ductal breast carcinoma and is HER2-positive and ER/PR negative. The clinical trial in question is looking to recruit women who have atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS). \n\nThe patient note does not mention ADH, ALH, or LCIS; instead, it mentions invasive ductal breast carcinoma, which is a different condition. Therefore, the patient does not meet the inclusion criteria for this clinical trial as the criteria specifically require a diagnosis of ADH, ALH, or LCIS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "95": {
        "output": "Let's evaluate the patient's eligibility for the clinical trial based on the provided inclusion and exclusion criteria:\n\nInclusion criteria analysis:\n- Histologically proven invasive unilateral breast cancer: The patient has invasive ductal breast carcinoma.\n- Initial clinical condition compatible with complete initial resection: The patient is a candidate for tumor resection.\n- No residual macro or microscopic tumor after surgical excision: The patient agrees to tumor resection prior to chemotherapy, which suggests that no residual tumor is expected after surgery.\n- Node-positive disease (N+): The patient has 5 positive lymph nodes.\n- Stage II or III disease: This is not explicitly stated, but the presence of positive lymph nodes and the tumor size (3 cm) suggest stage II or III.\n- pT >20 mm (T1-4): The tumor is 3 cm, which is greater than 20 mm.\n- Patients must meet one of the following hormone-receptor criteria: The patient's tumor is HER2-positive and ER/PR negative, which does not meet the specified hormone-receptor criteria for node-positive patients in the trial.\n- Must be able to begin chemotherapy no later than day 49 after the initial surgery: This is not mentioned, but since the patient agrees to surgery prior to chemotherapy, it's plausible that the timing can be managed accordingly.\n  \nExclusion criteria analysis:\n- Clinically or radiologically detectable metastases (M0): The patient has metastatic lesions on CXR, which indicates the presence of metastases.\n- Bilateral breast cancer or contralateral ductal carcinoma in situ: There is no information suggesting bilateral breast cancer or contralateral DCIS.\n- Any metastatic impairment: The presence of metastatic lesions on CXR indicates metastatic impairment.\n- Any tumor \u2265T4a: There is no information provided about cutaneous invasion, deep adherence, or inflammatory breast cancer.\n- HER2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive: The patient's tumor is HER2-positive, which is an exclusion criterion.\n\nBased on the exclusion criteria, specifically the presence of metastatic lesions and HER2 overexpression, the patient would be excluded from participating in the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "96": {
        "output": "Based on the provided patient note and clinical trial information, let's analyze the patient's eligibility for the clinical trial:\n\nPatient Characteristics:\n- 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative breast cancer\n- Metastatic lesions present (indicating metastasis)\n- Candidate for tumor resection\n\nClinical Trial Inclusion Criteria:\n- Patients undergoing radical hysterectomy or radical trachelectomy and pelvic lymphadenectomy\n- No evidence of metastases on imaging scans\n- Good surgical candidates\n- Signed informed consent\n- For patients of child-bearing age, a negative serum pregnancy test is required\n\nThe patient is postmenopausal, which satisfies the criteria concerning child-bearing potential. However, the patient has breast cancer with axillary involvement and metastatic lesions, which is not the target condition for the clinical trial. The trial is specifically targeting patients with cervical cancer undergoing a particular type of surgery (radical hysterectomy or radical trachelectomy and pelvic lymphadenectomy), and there is no indication that the patient in question is having this surgery or has cervical cancer.\n\nGiven this information, the patient does not meet the trial's inclusion criteria, which are specific to patients with cervical cancer undergoing specific surgical procedures. Since the patient has breast cancer, not cervical cancer, she does not qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "97": {
        "output": "Based on the information provided:\n\nThe patient is a 45-year-old postmenopausal woman, which matches the gender requirement of the clinical trial (female subjects).\n\nThe patient has invasive ductal breast carcinoma that is HER2-positive, which does not match the requirement of the clinical trial, which is looking for subjects with triple negative breast cancer (ER, PR, and HER2 negative).\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, indicating that she has not yet received the first-line treatment for her condition.\n\nThe clinical trial is looking for female subjects with triple negative breast cancer who have had prior adjuvant or neoadjuvant anthracycline-based chemotherapy, which this patient has not had.\n\nGiven that the patient's breast cancer is not triple negative and she has not received the specified type of chemotherapy, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "98": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, let's consider the key points:\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma in the left upper outer quadrant, 3 cm\n- HER2-positive, ER/PR negative\n- 5 positive lymph nodes from axillary sampling\n- Presence of metastatic lesions (CXR)\n- Candidate for tumor resection before chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Patients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.\n- ECOG performance status of equal to or less than 3.\n\nThe patient's note indicates that she has invasive ductal breast carcinoma and is a candidate for tumor resection, which may likely include axillary lymph node dissection as part of her treatment plan, aligning with the requirements of the trial. However, there is no mention of the patient's ECOG performance status, which is a necessary piece of information for determining her eligibility. Moreover, it is not specified whether the patient is planning to undergo her surgery specifically at M. D. Anderson Cancer Center, which is an inclusion criterion for the trial.\n\nGiven the information provided, the patient note does not contain sufficient information to determine the patient's ECOG performance status or confirm that her treatment will be at M. D. Anderson Cancer Center. Therefore, based on the available data, the assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "99": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's determine the patient's eligibility:\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- Metastatic breast cancer with 5 positive lymph nodes and metastatic lesions on CXR\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical trial inclusion criteria:\n- Signed study-specific Informed Consent Form(s)\n- Age \u2265 18 years\n- Histologically documented breast cancer\n- HER2-positive disease\n- Metastatic breast cancer\n- Disease progression on the last chemotherapy regimen received in the metastatic setting\n- Prior treatment with an anthracycline, trastuzumab, a taxane, lapatinib, and capecitabine in the neoadjuvant, adjuvant, locally advanced, or metastatic setting\n- Prior treatment with at least two lines of therapy in the metastatic setting, including at least two lines of anti-HER2 therapy\n- A minimum of 6 weeks of trastuzumab for the treatment of metastatic disease\n- At least 14 days of exposure in the metastatic setting to lapatinib and capecitabine (given together or separately) unless intolerant\n\nComparing the patient to the inclusion criteria:\n\n- The patient has signed the informed consent form (assumed as it's not mentioned but necessary for trial participation).\n- The patient is over 18 years of age.\n- The patient has histologically documented breast cancer.\n- The patient has HER2-positive metastatic breast cancer.\n- There is no information provided in the patient note about disease progression on the last chemotherapy regimen, prior treatments received, or duration of treatments such as trastuzumab, lapatinib, and capecitabine.\n\nDue to the lack of information regarding the patient's prior treatments and disease progression, we cannot conclusively determine whether the patient meets all the inclusion criteria. The patient does have HER2-positive metastatic breast cancer, which aligns with the study's target population, but without details on treatment history, we cannot make a full assessment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "100": {
        "output": "Patient Note Analysis:\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- The tumor is invasive ductal breast carcinoma in the left upper outer quadrant, 3 cm in size, HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- There are metastatic lesions noted on CXR.\n- The patient is a candidate for tumor resection and agrees to undergo the surgery before chemotherapy.\n\nClinical Trial Analysis:\n- The trial is looking for patients with histologically proven breast cancer (invasive adenocarcinoma).\n- The patients must have at least one axillary lymph node with evidence of tumor among a minimum of six resected lymph nodes.\n- Definitive surgical treatment must be either mastectomy or breast conserving surgery with axillary lymph node dissection.\n- Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma.\n- Patients must not have received any prior systemic anticancer therapy for breast cancer or prior anthracycline therapy or taxoids.\n\nComparison:\n- The patient in question has histologically proven breast cancer with positive axillary lymph nodes, which matches the inclusion criteria of the trial.\n- She is a candidate for tumor resection, which is required by the trial, though she has not yet undergone the surgery. To be eligible, the surgery must be completed with margins free of cancer.\n- She has not received prior systemic anticancer therapy for breast cancer, which meets the exclusion criteria.\n- However, we do not have information whether she has had a minimum of six lymph nodes resected or if the margins are free of cancer, as she has not yet undergone the surgery.\n\nConclusion:\nBased on the available information, the patient appears to meet some of the inclusion criteria but has not yet undergone the surgery required to confirm eligibility. The patient has not been excluded based on the exclusion criteria provided. However, without confirmation that the surgery has been completed and the outcome of the surgery, we cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    }
}